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We are proud to present the 26th General Report of Activities of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), which provides an overview of the 
agency’s key achievements in 2020, the year that marked the EMCDDA’s 25th anniversary.
When looking back at 2020, the first word that comes to mind, however, is ‘resilience’, as it 
was a year in which the EMCDDA, similar to other organisations in Europe and beyond, had 
to face a challenge that had never been seen before: the COVID-19 pandemic. Ever since 
the WHO declared a pandemic in March 2020, the way we live and the way we work have 
changed. It has also shown us how resilient we are, as an organisation, and as individuals.
Notwithstanding the need for teleworking, a great deal of which was required during the 
lockdown, the EMCDDA team rose to the challenge and managed to deliver some of the 
most successful products and services it has produced in recent times. These included 
35 scientific and corporate publications that, in addition to our other resources, generated 
great interest on the part of the 1.6 million people who visited the EMCDDA’s website 
during this extraordinary period.
While the year started with a clear list of priorities that were defined by our 2020 work 
programme, the organisation had to adapt swiftly to the new reality brought about by the 
pandemic. The priority, more than ever, was to serve our key customers – EU and national 
drug policymakers; practitioners in the Member States – with timely analyses of the impact 
of COVID-19 on drug use, services and markets. To that end, 11 new projects were kicked 
off, including trendspotting exercises, and a rich set of resources was produced and 
disseminated as a result.
As every challenge also brings an opportunity, for the EMCDDA this meant an acceleration 
of the digital transformation at all levels: core business and corporate. In the core business 
areas, highlights included the digital launch, with the European Commissioner for Home 
Affairs, Ylva Johansson, of our yearly flagship publication the European Drug Report 2020, 
in the form of a special anniversary edition that marked 25 years of EU drug monitoring. The 
EMCDDA’s training and capacity-building activities also went fully digital, benefiting close 
to 500 drug professionals, including health practitioners, law enforcement officers and 
policymakers both within the EU and beyond. The EMCDDA’s knowledge-transfer offer was 
also enriched in 2020 with the new webinar series – seven such events were organised on 
COVID-19, with an average of 200 participants per webinar.
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2020 also brought the first risk assessments on new psychoactive substances (NPS) 
carried out under the new legal framework on NPS that started to be applied in 2019. 
In that regard, three risk assessments were organised via teleconference by the newly 
appointed EMCDDA Scientific Committee. All three of the NPS in question have, in the 
meantime, been subject to control measures in the EU through delegated directives issued 
by the European Commission further to the evidence received from the EMCDDA.
At the corporate level, the EMCDDA mobility transformation programme was initiated. The 
objective of this important initiative is, by the end of 2021, to equip all of our staff members 
with modern and fully mobile workstations, which will increase flexibility and efficiency 
during remote or hybrid working.
2020 was also a year of enhanced partnership. The EMCDDA worked closely with its 
European partners, in particular with the Reitox network of national focal points. The agency 
offered them support throughout the year, and data on the impact of COVID-19 on the work 
of our main network was collected and published in a report drafted by the network itself in 
December.
Work in the area of international cooperation was scaled up in 2020 when the EMCDDA 
received funding from the European External Action Service to implement a bilateral 
technical assistance project with Georgia. This will add to the work performed in this area 
to implement the two ongoing EU-funded projects relating respectively to enlargement 
countries (Instrument for Pre-accession Assistance 7) and neighbouring countries 
(EU4Monitoring drugs).
2020 was also marked by the adoption, under the German Presidency of the Council, of 
the new EU drugs strategy for 2021-2025. The EMCDDA provided technical input to the 
preparation of the document, and the agency will be called to support its implementation in 
the years to come.
The 2020 roadmap of the EMCDDA Strategy 2025 came to an end during the year, and 
the Management Board was presented with the results of the successful implementation 
of this document. These results will inform the new roadmap, leading up to 2025, the 
preparation of which also started in 2020.
At the end of this challenging but transformative year, we would like to express our gratitude 
to the staff of the EMCDDA who, through their dedication and outstanding resilience, made 
all our achievements possible in 2020. We dedicate this General Report of Activities to 
them.
Our special thanks go to the members of the EMCDDA Management Board for their 
ongoing support and guidance, and to our Scientific Committee, which started its mandate 
in this challenging year of 2020.
Our final acknowledgement goes to the Heads and the staff of the Reitox National Focal 
Points and more broadly to all the networks and partners that enabled us to achieve our 
goals and gave us the privilege of contributing to their work in 2020.
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l List of acronyms and initialisms
ABAC electronic management and accounting system
BCP business continuity plan
CA contract agent
CEPOL EU Agency for Law Enforcement Training
CICAD Inter-American Drug Abuse Control Commission
COVID-19 coronavirus disease 2019
CND UN Commission on Narcotic Drugs
Copolad
Cooperation Programme between Latin America and the European Union on Drugs 
Policies
COM Communication unit
COSI Standing Committee on Operational Cooperation on Internal Security
DIR Directorate
ECA European Court of Auditors
ECDC European Centre for Disease Prevention and Control
ECDD Expert Committee on Drug Dependence
ECHA European Chemicals Agency
EDR European Drug Report
EFSA European Food Safety Authority
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
EMPACT European Multidisciplinary Platform Against Criminal Threats
EMSA European Maritime Safety Agency
ENP European neighbourhood policy
ESPAD European School Survey Project on Alcohol and Other Drugs
EU4MD EU4Monitoring drugs
Europol European Union Agency for Law Enforcement Cooperation




HEA Public health unit
IAS Internal Audit Service
ICF Internal Control Framework
ICS internal control standards
ICT information and communication technology
IPA Instrument for Pre-accession Assistance
JHA Justice and Home Affairs
KPI key performance indicator
LIBE Civil Liberties, Justice and Home Affairs
MoU memorandum of understanding
NFP national focal point
NGO non-governmental organisation
NPS new psychoactive substances
OAP operational action plan
OAS Organization of American States
RTX Reitox and external partners unit
SAS Risks to public safety and security unit
SDI Scientific coordination unit
SLA service-level agreement




UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
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Mission statement
Independent, science-based information is a vital resource 
to help Europe understand the nature of its drug problems 
and better respond to them. It was based on this premise, 
and in the face of an escalating drugs phenomenon, that the 
European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) was established in 1993. Inaugurated in Lisbon in 
1995, it is one of the EU’s decentralised agencies.
Building on the EMCDDA’s founding regulation (Regulation 
(EC) No 1920/2006) as amended (Regulation (EU) 2017/2101 
as regards information exchange on, and an early warning 
system and risk assessment procedure for, new psychoactive 
substances (NPS)), the EMCDDA Strategy 2025 defines the 
agency’s current mission and vision statements.
l Mission
The EMCDDA exists to support evidence-based decisions 
and actions at the EU and national levels by providing factual, 
objective, reliable and comparable information concerning 
drugs and drug addiction, and their consequences. The 
EMCDDA’s mission is therefore grounded in the consensus 
that sound information is a prerequisite for developing 
effective policies in the drugs area.
l Vision
The EMCDDA’s vision is a healthier and a more secure Europe, 
achieved through better-informed drug policy and action.
To do this effectively, the agency must constantly strive to 
respond to the needs of its primary customers, who can be 
defined as:
  EU institutions;
  national decision-makers/policymakers;
  professionals working in the drugs field.
Beyond meeting the information needs of its primary 
customers, to address its mandate the EMCDDA also needs 
to engage with other stakeholders, including academic 
institutions and researchers; the general public, civil society 
and those affected by drug problems; and international 
organisations and third countries.
l Values
The EMCDDA is committed to the EU and its values. Beyond 
these, the agency has identified its own set of core values to 
inform all aspects of its work, inspire staff in their professional 
performance, inform future organisational policies and guide 
the agency’s interactions with stakeholders and partners.
The EMCDDA’s four core values are:
  scientific excellence;
  integrity and impartiality;
  customer focus and service orientation;
  efficiency and sustainability.
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Management Board’s analysis 
and assessment
The Management Board has analysed and assessed the 
authorising officer’s (Director’s) General Report of Activities for 
the financial year 2020.
The Management Board appreciates the performance of 
the EMCDDA in implementing its work programme under 
unprecedented circumstances, while being innovative, for 
example through the rapid launch of a series of products and 
services on the impact of the pandemic on the drugs field, 
the webinars on specific topics and the virtual launch of the 
European Drug Report 2020.
The Management Board praises in particular the EMCDDA’s 
capacity to adapt to the challenges posed by the COVID-19 
pandemic, including by switching to telework and increased 
digitalisation.
The agency continued to show operational efficiency through 
the agile implementation of the 2020 work programme, and 
reached an outstanding level of budget execution, with 100 % 
of commitment appropriations executed.
In conclusion, the Management Board welcomes the 2020 
General Report of Activities, which provides an excellent 
overview of the agency’s achievements as set out in the work 
programme adopted by the Board.
General Report of Activities 2020 Executive summary
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Executive summary
This report presents the implementation of the activities of 
the EMCDDA’s work programme for 2020, the first year of the 
Programming Document 2020–22.
The report mirrors the work programme for 2020, which, in line 
with the EMCDDA Strategy 2025, presents the activities of the 
EMCDDA within the three main areas of work: health, security 
and business drivers.
While the EMCDDA has clear objectives and priorities in each 
area, it is important to note that the multifaceted nature of 
the drugs problem means that these areas are interlinked and 
complementary. Therefore, for the purpose of this executive 
summary, a section that includes transversal work is presented 
first.
l  Events that shaped the work of the EMCDDA in 2020
l COVID-19 pandemic
On 11 March 2020 the World Health Organization (WHO) 
declared coronavirus disease 2019 (COVID-19) a pandemic. 
As a result, and following the guidelines issued by the 
Portuguese authorities, the EMCDDA Director decided to 
activate the business continuity plan (BCP) on 13 March 
(Friday), at midnight. As of the next working day (16 March), 
the agency’s staff switched to teleworking mode.
While entering this new and challenging phase, the EMCDDA 
had to ensure the continuity of its operations and the 
protection of its 100+ staff members, while continuing to 
deliver some of its most valuable products and services to its 
key customers.
Acting in a highly responsive manner, in March, shortly after 
the pandemic was declared, the EMCDDA set up a task force 
and developed a COVID-19 hub page bringing together well-
timed resources on the disease and its impact on both drug 
users and the professionals in the drugs field.
From that moment on, until the end of 2020, the EMCDDA 
acted with agility and managed to shift its priorities promptly 
to meet the emerging needs. Twenty-eight new projects 
were designed in a timely manner by the agency’s staff 
and approved by the Director, 11 of which were focused on 
COVID-19. This allowed the EMCDDA to release new resources 
and disseminate knowledge in innovative ways (such as online 
training sessions, meetings and webinars). The Reitox National 
Focal Points played a substantial role in supporting the Centre 
to swiftly adapt the work programme, as well as the tools and 
methodologies used, to the new context and emerging needs.
l 25 years of drug monitoring
In 2020 the EMCDDA celebrated its 25th year of operation. 
In the quarter of a century since it embarked on its first work 
programme the agency has witnessed radical changes in both 
the extent and the nature of the drugs problem.
In order to mark this important milestone for EU drugs 
monitoring, the EMCDDA rolled out a monthly stream of 
branded content highlighting the agency’s added value. This 
included a look back at 25 years of annual reporting on the 
drugs problem in Europe and a digital storytelling campaign 
(‘Voices’), launched on International Day against Drug Abuse 
and Illicit Trafficking (26 June). Through this campaign, the 
agency’s team and the wider community shared their stories 
on what the EMCDDA means to them.
l Transversal work: health and security
In 2020 the agency continued to produce timely and high-
quality information, together with strategic and situational 
analyses and threat assessments, to inform policy and 
practice. In this regard, the agency’s most tangible outputs are 
its publications, some of which are produced in cooperation 
with partners. In 2020, 35 scientific and institutional 
publications were produced by the EMCDDA. The agency 
also authored or co-authored 29 scientific articles and book 
chapters that were published in prestigious journals and 
publications, enhancing the agency’s scientific reputation.
General Report of Activities 2020 Executive summary
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Furthermore, over 1.6 million visitors accessed the EMCDDA 
website in 2020 (i.e. 4 500 visits per day).
One of the most downloaded resources was the European 
Drug Report 2020 – Trends and developments, the EMCDDA’s 
yearly flagship publication. The report was launched virtually on 
22 September, from Brussels, Paris and Lisbon, with a panel 
comprising Ylva Johansson, European Commissioner for Home 
Affairs, Laura d’Arrigo, Chair of the EMCDDA Management 
Board, and Alexis Goosdeel, Director of the EMCDDA. 
Accompanying the main report was a summary of the key 
issues (in 24 languages) and the ‘Statistical Bulletin 2020’, 
containing the European dataset underpinning the report.
Participation in drug-related events and in training and 
capacity building are complementary means for the EMCDDA 
to disseminate information, analysis and knowledge. Due to 
the COVID-19 pandemic, most on-site events were replaced 
by online activities. During the year, the agency managed to 
transfer its knowledge to close to 500 professionals working 
in the drugs field, including law enforcement officers and 
policymakers both in the EU and beyond. An additional 200 
people (on average) attended each of the seven webinars on 
COVID-19 that were organised by the EMCDDA.
Specific highlights from the EMCDDA’s work within the three 
main areas – health, security and business drivers – are 
presented below, and details can be found in the later sections 
of the report and in the annexes.
l Health area
Through its EMCDDA Strategy 2025, the agency is committed 
to contributing to a healthier Europe by addressing important 
drug-related public health concerns.
In this regard, the emerging priority in this area was to 
contribute timely information and resources to the fight against 
COVID-19.
To that end, the ‘EMCDDA update on the implications 
of COVID-19 for people who use drugs and drug service 
providers’ was released in March 2020, very shortly after the 
disease was declared a pandemic by the WHO.
In the following months, the EMCDDA carried out several 
trendspotter exercises centred on COVID-19 and drugs, 
the results of which were released rapidly to the interested 
groups. A rapid assessment was undertaken of the impact of 
COVID-19 on drug use and related harms, and on drug service 
provision and help seeking in Europe. This included a round 
of surveys, including a tailored web survey answered by over 
11 000 people who use drugs and a number of facilitated 
groups with experts. Findings were triangulated and reported 
via rapid reports and webinars.
During the year, the agency continued to act upon the key 
public health priorities that were defined in the EMCDDA 
Strategy 2025, namely to contribute to the reduction of 
drug-related deaths; to promote hepatitis C testing and 
treatment among people who inject drugs; and to promote the 
implementation of evidence-based prevention interventions.
To support the EU’s efforts in these critical areas, the EMCDDA 
launched new resources focusing on drug overdoses in 
Europe and the interventions in place to prevent them. It also 
continued its harm-reduction initiative to increase access 
to hepatitis C testing and improve linkage to care. Finally, it 
took further steps in implementing the European Prevention 
Curriculum through the roll-out in several countries of the 
‘training of trainers’ system that started in 2019, including 
a new online component.
In the area of NPS, the EMCDDA continued to implement 
the EU Early Warning System (EWS) in collaboration with its 
EU partners. The EU EWS was formally notified for the first 
time of 46 NPS during the year, bringing the total number of 
NPS currently monitored to around 830. Furthermore, six risk 
communications were issued to the EU EWS network.
Furthermore, risk assessments for three NPS were carried 
out by the extended EMCDDA Scientific Committee via 
teleconference. These were the first risk assessments 
conducted under the new NPS legislative framework, 
within shorter deadlines and under teleworking conditions, 
which added to the complexity of the task. One of these 
new substances, isotonitazene, was placed under control 
in the EU by a Commission delegated directive adopted in 
September 2020. The delegated directive tackling the other 
two substances, MDMB-4en-PINACA and 4F-MDMB-BICA, was 
adopted in March 2021.
Risk communications and reports accounting for the potential 
impact of the COVID-19 pandemic on the drug markets and 
risks to people who use NPS were issued during the year, 
including one alert on the subject, three situation reports and 
an EWS update on NPS.
In the policy area, much of the agency’s efforts continued to 
focus on following up on the developments in the evolving 
cannabis market in order to promptly inform the EU policy 
debate. To that end, two new reports were released, and 
regular cannabis policy news items were issued on relevant 
European and international developments in this field. 
A meeting of EU agencies was also organised on the topic in 
February.
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An ongoing priority in the policy area was to contribute to 
implementing the EU action plan on drugs 2017–2020 and 
to support the European Commission, as required, in the 
evaluation of the EU drugs strategy 2013–2020. Furthermore, 
the EMCDDA provided input, upon request, to the Commission 
and to the German Presidency of the Council in relation to the 
development of the new EU strategy and action plan on drugs 
for 2021–2025.
The information and analysis provided by the EMCDDA in 
the health area were supported by the ongoing, underlying 
monitoring work that was carried out by the agency 
throughout the year. The core monitoring activity (based on 
the five EMCDDA key epidemiological indicators) was further 
strengthened, with a significant contribution from the Reitox 
network of national focal points (NFPs), the agency’s main data 
providers in the Member States. All meetings took place online 
in 2020.
A key publication in 2020 was the ESPAD Report 2019, which 
was launched online in November and the findings of which 
were discussed with experts during an EMCDDA webinar.
New data sources also continued to be developed and 
implemented. These leading-edge indicators provide useful, 
timely and complementary data that offer valuable insights 
into drug use in Europe. To that end, the EMCDDA enhanced 
its collaboration with innovative initiatives, including the 
Sewage Analysis Core Group Europe on wastewater analysis, 
the European Web Survey on Drugs (providing data on drug 
consumption in different populations of drug users in 16 
European countries), the European Drug Emergencies Network 
(an organisation that monitors emergency data on acute 
drug-related harm that are provided by selected hospitals in 
18 European countries), the European Syringe Collection and 
Analysis Project Enterprise (ESCAPE) and the Trans-European 
Drug Information Project (TEDI). Data collected from the 
EMCDDA’s collaboration with these initiatives fed into many 
of the EMCDDA’s analyses that were produced and published 
during the year.
l Security area
The EMCDDA further disseminated the joint EMCDDA–
European Union Agency for Law Enforcement Cooperation 
(Europol) EU Drug Markets Report 2019, which was released 
in November 2019. The agency’s efforts in this regard included 
a presentation by the Director at the European Parliament in 
January 2020.
Much of the agency’s work in 2020 was dedicated to 
investigating the impact of COVID-19 on the drug markets. This 
included the release in May of a new EMCDDA and Europol 
joint publication titled EU Drug Markets – Impact of COVID-19. 
This was complemented by a special report on COVID-19 
and Drugs – Drug supply via darknet markets, which was 
published in the same month.
In the policy area, the EMCDDA provided technical input and 
advice to EU institutions, on request, on issues such as drug 
activity on darknet markets and on the preparation of the new 
EU strategy and action plan on drugs 2021–2025 and the new 
EU security union strategy for 2020–2025.
Furthermore, the agency continued to contribute to the 
European Multidisciplinary Platform against Criminal Threats 
(EMPACT) operational action plans (OAPs) of the EU policy 
cycle on organised and serious international crime. This 
included providing input on the drafting of the EMPACT OAPs 
for 2021 on NPS / synthetic drugs and on cannabis, cocaine 
and heroin; and delivering drug-related training activities for 
387 law enforcement professionals alongside the European 
Union Agency for Law Enforcement Training (CEPOL).
To support the comprehensive analytical effort in the security 
area, work continued in 2020 on improving the quality and 
availability of core supply data, in close collaboration with 
the Reitox NFPs and with our EU partner Europol. In terms of 
new sources of data and innovative monitoring approaches, 
the EMCDDA further developed its capacity for open-source 
information and darknet monitoring, which have been gaining 
importance in relation to understanding the rapidly evolving 
and increasingly tech-savvy drug market. In addition, progress 




The EMCDDA Management Board took the unanimous 
decision on 25 June, following a proposal by the Commission, 
to renew the mandate of the agency’s Director, Alexis 
Goosdeel, for the next 5 years, until 31 December 2025.
The Director’s top priorities for the second half of his mandate 
include the digital transformation of the EMCDDA and the 
development of a new business model to help the agency 
contribute more efficiently to a healthier and more secure 
Europe. To this end, the EMCDDA business model innovation 
initiative began in 2020, with the objective of redesigning the 
way the agency creates and delivers value to its key customers: 
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policymakers at the EU and national levels and practitioners in 
the Member States.
l  Communication and service delivery to meet evolving EMCDDA customer needs
The COVID-19 pandemic brought about significant changes 
in the way the world communicated in 2020. Furthermore, it 
reshaped the needs of the EMCDDA’s key customers, namely 
policymakers at the EU and national levels and practitioners 
in the EU Member States. To that end, priority was given 
to ensuring that products and services were provided in 
a timely manner to these customers via the agency’s digital 
channels. These included online training courses and events 
(e.g. webinars) and product launches (e.g. the launch of the 
European Drug Report 2020 and many COVID-19-related 
products).
Further activities were carried out to enhance engagement 
with the agency’s audience, in particular via online 
communication channels. As a result, the upward trend in 
the number of social media followers continued in 2020, with 
an increase observed for all channels (e.g. a 9 % increase 
in Facebook followers and a 73 % increase in Instagram 
followers).
Finally, the ‘Customer needs’ initiative, which started in 2018, 
made further progress in 2020. During the year, a framework 
for proactively identifying and responding to stakeholders’ 
needs was developed and prepared for staff testing. The 
framework consists of a collection of methods and instruments 
such as customer journey mapping, needs and gap analyses, 
personas, surveys, online consultations, face-to-face (semi-
structured) interviews, focus groups, workshops, metrics 
and staff training. The next step will be to link this dynamic 
framework to the EMCDDA business model innovation 
initiative.
l Working in partnership
In fulfilling its tasks, the agency relies on a large number of 
partners, and in particular the Reitox network of NFPs, which 
plays a critical role in sustaining the EU core monitoring 
system. 2020 saw the completion of the first Reitox 
development framework roadmap (2017–2020), and the 
EMCDDA initiated, with input from the NFPs, an assessment 
of the implementation of this document. The results will inform 
the joint preparation of the second roadmap (2021–2025), 
which will be presented to the heads of NFPs for adoption in 
2021.
The EMCDDA also took stock of the effects of the COVID-19 
pandemic on the work of the NFPs. The report EMCDDA 
National Focal Points’ Activities during the COVID-19 
Pandemic was released in December. The report concluded 
that in the course of the year the NFPs performed many extra 
activities, including launching new COVID-19-related surveys, 
creating and providing national guidelines, disseminating 
information to drug users and the staff of drug services and 
providing new services.
In performing its work and achieving its objectives, the 
EMCDDA also relies on its other EU and international partners. 
Together with the other eight EU agencies that are members 
of the Justice and Home Affairs (JHA) Agencies’ Network, 
the EMCDDA contributed to a joint paper on the COVID-19 
response by the JHA agencies, which captures the agencies’ 
individual and joint efforts to deal with the impact of the 
pandemic. The document was formally endorsed by the heads 
of the JHA agencies during a videoconference held on 9 July.
In terms of international organisations, in February the 
EMCDDA and the Pompidou Group of the Council of Europe 
adopted an appendix to the memorandum of understanding 
(MoU) signed between the two organisations in 2010. 
Furthermore, in Washington DC, in January, the EMCDDA 
and the Inter-American Drug Abuse Control Commission 
(CICAD) signed a new work programme for the 2019–2024 
period, under the MoU signed with CICAD’s parent body, the 
Organization of American States (OAS), in 2000.
In terms of cooperation with third countries, the EMCDDA 
signed two new working arrangements – with Kosovo(*) in 
September and with Serbia in December – via an exchange 
of letters between the EMCDDA and the respective national 
authorities.
In this area, the agency continued to cooperate with 
enlargement countries and to implement technical cooperation 
projects under the Instrument for Pre-accession Assistance 
(IPA). In this regard, the IPA 7 project entered its second year 
of implementation. Entitled ‘Stepwise integration of the IPA 
beneficiaries in the activities of the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) and the Reitox 
network’, the project, which has a total budget of EUR 1 million 
and is planned to run until June 2022, aims to enhance the 
capacity of the EU and the six IPA beneficiaries to detect, 
analyse and report on emerging drug-related health and 
security threats.
(*) This designation is without prejudice to positions on status and is in line with 
UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of inde-
pendence.
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Cooperation with European neighbourhood policy (ENP) 
partner countries also continued through the technical 
assistance project ‘EU4monitoring drugs’ (EU4MD), financed 
by the European Neighbourhood Instrument. It is planned 
that the project, which has a total budget of EUR 3 million, will 
run until June 2022 (extended from December 2021), with 
the objective of supporting national and regional readiness in 
the ENP area (for 15 potential partner countries) to identify 
and respond to drug-related health and security threats. In 
2020, a significant number of project outputs were released, 
including the report Emerging evidence of Afghanistan’s 
role as a producer and supplier of ephedrine and 
methamphetamine, which generated a great deal of interest 
among EMCDDA stakeholders and media across the world. 
The project also published a pair of reports on the impact of 
COVID-19 on drug markets in the eastern and the southern 
ENP countries.
In 2020 the Commission also granted EUR 800 000 in funding 
to the EMCDDA to implement its first bilateral project with 
Georgia. The new project, called EMCDDA4GE, will start in 
2021, with a duration of 24 months.
l Scientific capacity
2020 marked the beginning of the 2020–2022 mandate of the 
EMCDDA’s newly appointed Scientific Committee, following its 
official appointment by the Management Board in December 
2019.
At the committee’s 52nd meeting, which took place virtually 
on 13 November, Prof. Dr. Catherine Comiskey (Ireland) was 
elected to the position of Chair and Prof. Dr. Henri Bergeron 
(France) to the position of Vice-Chair for the 2020–2022 
period.
In 2020 the EMCDDA finalised the implementation of the 
first futures exercise to analyse current and potential future 
global changes and their implications for the European 
drug monitoring system until 2030. This involved a solid 
participatory approach and a series of workshops organised 
with key EMCDDA stakeholders. The exercise resulted in a set 
of recommendations on how to keep the EMCDDA’s tools 
and methods fit for purpose in the context of a changing 
information environment and new information needs.
l Corporate performance
Despite the impact of COVID-19 on its activities, in 2020 the 
EMCDDA managed to achieve a good level of performance in 
implementing its work programme.
While, as a consequence of the pandemic, some of its key 
performance indicators (KPIs) were not fully achieved (see 
Annex Ib), the agency showed remarkable resilience and 
continued to function without interruption throughout the 
year. Moreover, the EMCDDA provided proof of its high 
responsiveness, as the agency was able to release some 
high-value resources on the impact of COVID-19 on drug 
users, drug markets and drug services in a timely way. In 
doing so, the agency acted as an agile organisation that was 
successful in shifting priorities rapidly and reallocating its 
resources efficiently to that effect. Once again the agency 
reached an outstanding level of budget execution, with 100 % 




Report of activities: key achievements 
of the year
l Main area 1: Health
l Core monitoring
In 2020 the EMCDDA celebrated 25 years of monitoring the 
drug situation in Europe. In the quarter of a century since 
it embarked on its first work programme, the agency has 
witnessed radical changes, in both the extent and the nature of 
the drugs problem.
FIgURe 1. ‘25 years of monitoring’ logo
The annual core data-collection and management activities are 
key tasks set up in the EMCDDA’s founding regulation. These 
are implemented every year in close collaboration with the 
agency’s main data providers, namely the Reitox network of 
NFPs in the EU Member States, Norway and Turkey.
Revolutionary changes, both in the extent and the nature of the 
drugs problem and in the world in which we live, have called 
for constant reflection, innovation and agility to keep pace with 
new developments and rethink existing routines. This is why, in 
its response to a fast-moving drugs problem, the EMCDDA has 
adopted a multi-indicator approach to monitoring.
Central to this core monitoring activity are the five key 
epidemiological indicators:
  GPS, which describes the prevalence and patterns of drug 
use among the general population;
  PDU, which focuses on the prevalence and patterns of 
high-risk drug use;
  TDI, which is the treatment demand indicator;
  DRD, which describes drug-related deaths and mortality 
among drug users;
  DRID, which describes drug-related infectious disease.
By supplementing data routinely submitted by Member States 
with information from an expanding range of leading-edge 
sources, as shown in Figure 2, the agency can now respond 
with more timely and rounded analyses to inform drug policies 
and practices in the years to come.
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FIgURe 2. EMCDDA preparedness and response
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with revolutionary changes in the extent and nature of the drugs problem and in the world in which 
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Hospital emergency data analysis
EU Early Warning System
Web surveys
Darknet market monitoring
Drug-checking services data analysis
Syringe residue studies 
Open source information monitoring 
Risk assessments on outbreaks of infectious diseases
Cannabis policy alerts
Monitoring the prevalence and patterns of drug use plays 
a vital role in our understanding of the drug situation in Europe.
The worldwide health crisis brought about by the COVID-19 
pandemic in early 2020 raised serious additional concerns 
relating to the wellbeing of people who use drugs; ensuring 
service continuity for those with drug problems; and protecting 
those offering care and support for this population.
For this purpose, the EMCDDA set up a new COVID-19 hub 
page to bring together a selection of resources on the disease 
and its impact on people who use drugs and those providing 
services to them . The resources include publications, news 
material, documents and external links that reach out to drug 
service providers, people who use drugs and prison services.
Further information on COVID-19-related resources and 
activities undertaken can be found later in the report.
In August 2020 the EMCDDA published its latest update on 
‘Take-home naloxone’, including updated country profiles and 
factsheets from the countries concerned, along with a new 
online knowledge questionnaire on overdose and take-home 
naloxone aimed at both those likely to witness an overdose 
and the wider interested public (available in four languages – 
English, French, German and Spanish).
During European Testing Week, in May 2020, the EMCDDA 
released its latest update on drug-related infectious diseases 
in Europe among people who inject drugs, stressing that early 
diagnosis through testing and improving links to treatment and 
care are crucial steps towards protecting this vulnerable group 
and reaching global health goals.
Analytical work was further developed to inform key EMCDDA 
outputs, in particular the European Drug Report 2020 package.
European Drug Report 2020: in the spotlight
High availability across all drug types, drug production 
within Europe and highly potent substances are 
among the concerns addressed in the European Drug 
Report 2020 – Trends and developments. In this 
latest EMCDDA annual review – marking 25 years of 
monitoring – the agency described the drug situation at 
the end of 2019, along with recent changes caused by 
the COVID-19 pandemic in early 2020.
The official launch of the European Drug Report 2020 
took place virtually on 22 September, from Brussels, 
Paris and Lisbon, with a panel comprising Ylva 
Johansson, European Commissioner for Home Affairs, 
Laura d’Arrigo, Chair of the EMCDDA Management 
Board, and Alexis Goosdeel, Director of the EMCDDA. 
A total of 495 people attended the event, including 67 
journalists and 428 stakeholders.
The Commissioner stated that ‘This report shows that 
illicit drugs remain a threat to the health and security 
of EU citizens.’ She added that the publication was ‘an 
essential source of reference, data and information.’
Accompanying the main report on trends and 
developments was a summary of the key issues  
(in 24 languages), presenting a selection of the main 
findings from the latest analysis, chosen for their policy 
relevance and general interest.
The ‘Statistical Bulletin 2020’, containing the European 
dataset underpinning the report, was also made 
available. In addition, a video, two news releases 
(‘Taster’ in English and ‘Highlights’ in 24 languages), 
a special edition of the newsletter Drugnet Europe and 
a promotional brochure were produced by the agency to 
mark the launch of the European Drug Report 2020.
FIgURe 3. Video of Commissioner Ylva Johansson on 
the occasion of the launch of the European Drug Report
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When looking back at 25 years of annual reporting on the 
drugs problem in Europe the EMCDDA’s Scientific Director 
states that:
EMCDDA Scientific Director Paul Griffiths
Two things stand out: first, Europe’s drugs problem has 
evolved considerably over this period; and second, this 
evolution has been accompanied by a dramatic increase in 
the quantity and quality of the information available on the 
topic.
An article by Paul Griffiths, the EMCDDA’s Scientific Director, 
which was released in September, describes reporting 
through various EU enlargements and a rapidly changing drug 
landscape, and shows how information needs for informed 
policies have evolved over time.
Support for those third countries that are a priority for the EU 
continued under the framework of the technical assistance 
projects IPA 7 and EU4MD (for details see ‘Business driver 2: 
Partnership’).
Work in the area of drugs and prisons continued during 2020, 
and will culminate in the launch of an in-depth review on 
current and future challenges in the prison and drugs field in 
2021.
ESPAD Report 2019: in the spotlight
FIgURe 4. ESPAD Report 2019
Smoking and drinking among 15–16-year-old school 
students are showing signs of decline, but there are 
concerns over potentially risky cannabis use and the 
challenges posed by new addictive behaviours.
These were among the findings in a new report from the 
European school survey project on alcohol and other 
drugs (ESPAD), published in collaboration with the 
EMCDDA.
Almost 100 000 students participated in the 
latest survey round, responding to an anonymous 
questionnaire.
The ESPAD Report 2019 was launched online on 
12 November, and the findings were discussed with 
experts during an EMCDDA webinar, which was 
attended by 450 participants.
A video was also produced highlighting the main 
messages of the report (see Figure 5).
FIgURe 5. ESPAD highlights video
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l  Responding to new psychoactive substances: EU Early Warning System and risk assessment
In 2020 the EMCDDA continued to ensure the robust 
implementation of the EU EWS on NPS, under the EU 
legislative framework on NPS (1), and in close collaboration 
with its partners in the Member States (the Reitox network 
of EWS correspondents) and partner EU agencies (the 
European Centre for Disease Prevention and Control (ECDC), 
the European Chemicals Agency (ECHA), the European Food 
Safety Authority (EFSA), the European Medicines Agency 
(EMA) and Europol).
Key outputs from the EWS included risk communications 
issued to the EWS network, namely rapid formal notifications 
of the first detection in Europe of new substances, public 
health alerts on NPS, the exchange of forensic and 
toxicological analytical data, and outputs relating to the 
implementation of the new NPS legislation.
In a nutshell, the EMCDDA’s main activities in this area were as 
follows.
  Case reports on 46 NPS detected for the first time in the 
EU were received, processed and analysed – literature 
available for each of those substances was assessed, 
and available information was appraised prior to issuing 
the formal notifications to the EU EWS network. Prior 
to the formal notification, a rigorous assessment takes 
place based on the literature available, the analytical 
data submitted and the comparison of the substance 
with better-known substances, to determine whether 
the substance falls within the definition of an NPS and 
whether the data provided on the detection is sufficient. 
Only those substances that meet the criteria are formally 
notified to the network.
  Around 830 NPS were monitored by the EU EWS, as of the 
end of 2020.
  Six risk communications, including four advisories and two 
alerts, were issued to the EU EWS network.
  Three situation reports were issued to the EU EWS 
network. Situation reports are a new type of publication 
launched under the lockdown that aim to strengthen 
situational awareness and to help the network to prepare 
for, respond to and recover from public health and social 
threats caused by NPS.
(1) From 23 November 2018, Council Decision 2005/387/JHA was replaced by 
Regulation (eU) 2017/2101 of the european Parliament and of the Council 
of 15 November 2017 amending Regulation (eC) No 1920/2006 as regards 
information exchange on, and an early warning system and risk assessment 
procedure for, new psychoactive substances.
  Three initial reports – on isotonitazene, 4F-MDMB-BICA 
and MDMB-4en-PINACA – were launched, prepared and 
submitted to the Council and the Commission within the 
deadlines stipulated by the NPS regulation.
  Risk assessments of isotonitazene, 4F-MDMB-BICA, and 
MDMB-4en-PINACA were carried out by the EMCDDA, 
and the respective technical reports and risk assessment 
reports were submitted to the Commission and the 
Member States within the deadlines stipulated by the NPS 
regulation.
Operation of the EU Early Warning System
FIgURe 6. New psychoactive substances monitoring 
in 2020
Network management and the provision of technical 
assistance on a daily basis to the members of the Reitox EWS 
network continued to be among EMCDDA’s central activities. 
This was particularly important, and challenging, in 2020 due 
to the COVID-19 pandemic. This obliged both the EMCDDA 
and its partners to switch to teleworking for most of the year. 
Notwithstanding these constraints, the EU EWS continued to 
run without interruption.
The 20th annual meeting of the Reitox EWS network took place 
via videoconference on 10 November, with the participation 
of the 27 EU Member States, Norway and Turkey. All the 
presentations given at this meeting and the minutes of the 
proceedings were published in the European Database on New 
Drugs.
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The EMCDDA played an important role in the organisation of 
the Seventh International Conference on Novel Psychoactive 
Substances, jointly with the International Society for the Study 
of Emerging Drugs, the United Nations Office on Drugs and 
Crime (UNODC), the World Anti-Doping Agency, the University 
of Hertfordshire and The Center for Forensic Science Research 
& Education. Due to the COVID-19 pandemic, the conference 
was held online on 18 and 19 November. The EMCDDA, 
as a key member of the Scientific Conference Committee, 
designed the scientific programme and contributed several 
keynote presentations.
Reflecting the world-leading expertise and role played by 
the EMCDDA in the NPS area, particularly in relation to early 
warning, the agency provides information, expertise and advice 
each year to the UNODC and the WHO. In particular, it collated 
and sent to the UNODC information on all NPS detected in 
the Member States in 2019, including a list of NPS formally 
notified in the first semester of 2020. The EMCDDA also 
provided the WHO Expert Committee on Drug Dependence 
(ECDD) with data for the prioritisation process and for the 
preparation of critical reviews, which informed the discussions 
held at the 43rd ECDD meeting.
The agency’s work with those third countries that are a priority 
for the EU, namely candidate and potential candidate 
countries, continued in 2020 under the framework of the IPA 7 
project (see ‘Business driver 2: partnership’). In that regard, the 
representatives of Montenegro and Serbia attended the online 
annual meeting of the Reitox EWS network. Other project 
activities in this area had to be cancelled, however, due to the 
travel restrictions related to the COVID-19 pandemic.
Risk assessments on new psychoactive substances
Under the latest legislation, to ensure a stronger and faster 
response to NPS, initial reports are drawn up on NPS that may 
pose health or social risks at the EU level.
In that regard, the initial report on isotonitazene was 
submitted to the Commission and the Member States on 
3 April. Based on the findings of the report, the Commission 
requested that the EMCDDA carry out a risk assessment on 
this substance. The risk assessment meeting was conducted 
via videoconference on 26 May; consequently, the technical 
report and the risk assessment report on isotonitazene 
were submitted to the Commission and the Member States 
on 29 May, within the 6-week deadline stipulated by the 
regulation.
On 13 November, Commission Delegated Directive (EU) 
2020/1687 of 2 September 2020 was published in the 
Official Journal of the European Union. Entering into force 
on 3 December, this delegated directive will lead to the new 
synthetic opioid isotonitazene being placed under control in 
the EU. The Member States will have until 3 June 2021 to bring 
into force the laws, regulations and administrative provisions 
necessary to comply with this directive. This is the first ban 
under the revised EU legislation on psychoactive substances.
Furthermore, two initial reports – on 4F-MDMB-BICA and 
MDMB-4en-PINACA – were launched by the EMCDDA and 
submitted to the EU institutions on 14 October, within the 
stipulated deadline. As a result, the Commission asked the 
EMCDDA to carry out risk assessments on the two substances. 
The risk assessments meeting was once again conducted 
New psychoactive substances and the COVID-19 pandemic: in the spotlight
FIgURe 7. EMCDDA rapid communication on NPS and 
the COVID-19 pandemic
The EMCDDA rapid communication New psychoactive 
substances: global markets, glocal threats and the 
COVID-19 pandemic – An update from the EU Early 
Warning System was published in December.
Covering the period from 2005 to October 2020, the 
report encourages the reader to reflect on how the 
issues highlighted may apply to their country, region 
or neighbourhood, and on how the pandemic may be 
having an impact.
The update includes recent developments in NPS use 
and the market and highlights emerging threats. It also 
underlines the need to continue to invest in developing 
and maintaining strong early-warning and response 
systems for NPS and illicit drugs to protect public health.
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by the EMCDDA via videoconference, on 7 December. 
Subsequently, the technical reports and risk assessment 
reports on the two substances were submitted to the 
Commission and the Member States on 9 December.
On the basis of the risk assessments, the Commission decided 
to propose control measures on these substances. The 
Commission delegated directive bringing 4F-MDMB-BICA and 
MDMB-4en-PINACA under control in the EU was adopted on 
12 March 2021.
Acknowledging the EMCDDA’s contribution in this area, in 
March 2021 the European Commission stated:
Thank you for all your hard and excellent work on the initial 
reports and the risk assessment reports and for your all your 
support to the Commission in the preparation of this delegated 
act. And all this under difficult circumstances due to the on-
going pandemic.
In addition to initial reports and risk assessment reports, 
a range of other activities inform policymaking in the EU and 
in the Member States. For instance, the EMCDDA provided 
data and technical advice on the common position to be taken 
by the EU on the scheduling of substances under the UN 
conventions and on the draft delegated directives controlling 
the substances that were risk-assessed.
The EMCDDA operating guidelines for the risk assessment of 
new psychoactive substances were published in December. 
The purpose of these guidelines is to ensure compliance with 
the scope and requirements of Regulation (EC) No 1920/2006 
(as amended) and Council Framework Decision 2004/757/
JHA (as amended) in respect of the risk assessment procedure 
for and reporting on NPS.
To operationalise the technical aspects of the risk assessment, 
the guidelines are supported by a set of guidance notes 
developed by the EMCDDA.
l New trends and health threats
To improve the timeliness of reporting, it is crucial that new 
and flexible monitoring tools complement the EMCDDA’s core 
monitoring system. In 2020 the agency further developed and 
strengthened its system for monitoring and understanding new 
and emerging trends in drug use and drug markets.
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Data from hospital emergency departments show that every 
year in Europe thousands of individuals experience drug-
related toxicity, which results in emergency presentations 
to hospital. The latest findings from the European Drug 
Emergencies Network on hospital emergencies were 
presented in an EMCDDA report released in February.
The latest findings from the largest European project in the 
emerging science of wastewater analysis were presented 
in March by the Europe-wide Sewage Analysis Core Group 
Europe, in association with the EMCDDA. The project analysed 
wastewater in 68 cities, located in 23 European countries, to 
explore the drug-taking behaviours of their inhabitants.
In 2020, new findings from the ESCAPE network were 
analysed (published in early 2021). The analysis is the result 
of an innovative project investigating the substances used by 
people who inject drugs, by chemically analysing the content 
of used syringes. In addition, data collected from the Trans-
European Drug Information Project were analysed throughout 
the year.
 
Furthermore, the agency endeavoured to anticipate the 
developments in the EU drug situation through a participatory 
‘Futures’ exercise, aimed at analysing current and potential 
future global changes and their implications for the European 
drug monitoring system until 2030. This led to a series of 
events in 2020, including the organisation of two internal 
face-to-face workshops in February and a ‘Futures Policy 
Workshop’ in September involving participants from the EU 
institutions and 16 different EU Member States. The exercise 
Trendspotter studies on COVID-19: in the spotlight
Since the start of 2020, European countries have been 
experiencing an unprecedented public health threat 
with the emergence of COVID-19. In order to investigate 
the effects of this pandemic on people who use drugs 
in Europe, and the implications for them, the EMCDDA 
instigated a mixed-method trendspotter study to 
investigate the current situation (see Figure 8).
As Europe grapples with the unprecedented public 
health threat posed by COVID-19, how is the outbreak 
affecting drug users and service providers? The question 
that the EMCDDA examined in a trendspotter study 
published in May: ‘Impact of COVID-19 on drug services 
and help-seeking in Europe’. The report provided 
evidence of a decline in the availability of drug services 
and in the numbers of those seeking help.
A further briefing published in June provided a snapshot 
of the state of play with respect to the impact of 
COVID-19 on drug-consumption patterns and drug-
related harms during the early stages of the pandemic. 
The report described how national confinement 
measures and disrupted street drug markets have 
reduced both the opportunities to use drugs within 
social environments and the availability of some 
substances. But it also suggested a rise in the use of 
alcohol and prescription medicines, in some groups, as 
a means of coping with anxiety and depression during 
lockdown.
As part of the study, information on the impact of 
COVID-19 on people who use drugs, and on the services 
that support them, was collected via a special round 
of the European Web Survey on Drugs, launched in 
April. The survey, available in 18 languages, gathered 
information on how patterns of drug use, access to 
health services and the drug market may have changed 
in Europe during the pandemic.
FIgURe 8. Adapted trendspotter methodology, April 2020
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was based on a horizon-scanning approach, which is a holistic, 
360-degree analysis of the general environment – a study of 
events and trends affecting the drug area but going beyond 
the drugs or addiction field, and even the European region (see 
Figure 9). The objective was to examine main drivers of change 
that have, or may have in the future, implications for the drugs 
situation, drug monitoring and related responses. The set of 
recommendations defined by the exercise will help the agency 
to maintain an up-to-date understanding of the extent of 
drug use, patterns and trends and to identify future reporting 
needs. It will also inform the EMCDDA Strategy 2025 roadmap 
and the ongoing work on the new EMCDDA business model, 
in terms of keeping the EMCDDA’s tools and methods fit for 
purpose in the context of a changing environment and new 
information needs.
l Drug interventions
In 2020 the preparation of the second edition of the flagship 
EMCDDA publication Health and Social Responses to Drug 
Problems – A European guide was initiated, with plans 
for publication in 2021. This included the commissioning 
of a round of background papers on new topics including 
migration and drugs, homelessness and image- and 
performance-enhancing drugs.
Best Practice Portal
Identifying the best practices among interventions across 
the EU and beyond, and the factors determining their 
effectiveness, is a key area of work for the EMCDDA, and the 
main dissemination channel for this information is the Best 
Practice Portal.
In 2020, existing modules were kept updated and new 
modules were added on the following topics, among others:
  evidence updates on social-reintegration- and 
employment-focused interventions;
  substitution treatment for stimulant users;
  evidence-based interventions for vulnerable populations;
  pharmacotherapy for amphetamine and 
methamphetamine use.
In December, a new protocol for updating the ‘Evidence’ 
database of the Best Practice Portal, which is one of its key 
components, was released.
An additional important task was the further consolidation of 
the EMCDDA’s online databases on interventions in nightlife 
settings and evidence-based prevention programmes with 
online training tools.
Training and capacity building
Another effective means of disseminating best practices is 
through training activities. During the year several such events 
took place, including Reitox academies and other training 
initiatives, which were held in cooperation with traditional 
partners such as the University Institute of Lisbon. Due to 
the COVID-19 pandemic, most of the initiatives had to be 
organised virtually, while some were delayed due to the difficult 
circumstances for all the stakeholders involved.
A total of 49 participants from 30 countries attended the first 
fully online European Drugs Summer School, organised by the 
EMCDDA and the University Institute of Lisbon from 29 June 
to 10 July. Over half of the delegates were from outside the 
EU, hailing from Chile to Zimbabwe and Brazil to Myanmar/
Burma. Despite the time-zone differences, the average daily 
participation was 90 %, while satisfaction registered through 
weekly polls was high.
The European Prevention Curriculum continued to be 
implemented during 2020 in a number of countries through 
a ‘training of trainers’ system (initiated in 2019) and local 
translations of the curriculum itself. In October a Reitox 
Academy on European Prevention Curriculum: Training for 
Decision-, Opinion- and Policymakers took place (for details 
see ‘Business driver 2: Partnership’).
FIgURe 9. Environmental scanning 360-degree view
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Harm reduction
In 2020 the EMCDDA continued to promote good practices in 
harm reduction, including the integration of evidence-based 
practices, interventions and policies into routine healthcare 
and public health settings.
Work was initiated in partnership with the ECDC on 
an update of guidance on the prevention of infectious 
diseases among people who use drugs. A new project also 
focused on the evidence for the use of drug equipment in 
intervention settings. As part of its harm-reduction initiative 
to increase access to hepatitis C testing and improve linkage 
to care, on 28 July the EMCDDA promoted its knowledge 
questionnaire designed for those working in drug treatment 
settings. The main aim of the questionnaire is to allow those 
working in such services to refresh their knowledge of the 
hepatitis B and C viruses, including transmission, testing and 
care for people who inject drugs. The questionnaire is available 
in seven languages (Dutch, English, French, German, Italian, 
Polish and Portuguese). This is to be used alongside planned 
EMCDDA barometers aiming to help countries monitor 
progress against the UN’s sustainable development goals.
The EMCDDA also organised a workshop to support countries 
in designing a national diagnostic process aimed at identifying 
barriers and opportunities to support hepatitis C testing and 
care in drug services through a participatory approach.  
The meeting with national representatives provided an 
opportunity to test and finalise the key EMCDDA documents in 
the hepatitis C virus area to be available in 2021.
EMCDDA COVID-19 webinars: in the spotlight
In 2020 the EMCDDA offered a new series of 
webinars around the theme of COVID-19. Between 
May and December the EMCDDA hosted seven 
COVID-19 webinars, designed to help those working 
in the drugs field understand how drug users, 
and those supporting them, were coping with the 
pandemic and to share knowledge and experience 
(see Figure 10).
An average of 200 participants (representing 73 
countries in total) attended these online events. 
The webinars allowed for discussions on emerging 
challenges. Later in the year the EMCDDA organised 
an additional webinar on ESPAD (see ‘Main area 1: 
Health’ for details).
FIgURe 10. EMCDDA COVID-19 webinars 2020
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l Drug policies
Support for drug policy at the EU level
Throughout the year, the EMCDDA continued to provide 
technical input and advice to drug policymakers at the EU 
level, namely to the European Parliament, the Council of the 
European Union and the European Commission, and also to 
policymakers in the Member States, as they are key EMCDDA 
customers.
Regarding the European Parliament, ongoing contact was 
maintained. The EMCDDA Director met several members of 
the European Parliament and gave presentations at three 
meetings of the Parliament’s Committee on Civil Liberties, 
Justice and Home Affairs (LIBE Committee), on 28 January, 
on 4 June (online) and on 27 October (online) (see ‘EMCDDA 
Director: main activities’).
Concerning the Council, the agency provided support to the 
Croatian and German Presidencies. While many of the year’s 
regular meetings were cancelled due to COVID-19, the agency 
attended the remaining institutional and technical meetings 
by invitation. These included nine meetings of the Horizontal 
Drugs Group (seven of which were remote meetings) and 
the online meeting of national drugs coordinators that was 
organised by the German Presidency on 14 October. The 
EMCDDA also contributed to the meetings of the Council’s 
Standing Committee on Operational Cooperation on Internal 
Security (COSI) and to EU expert dialogues such as those of 
the EU–Community of Latin American and Caribbean States, 
the Dublin Group, the EU–Argentina, the EU–Russia and the 
EU–Civil Society Forum on Drugs, along with the Horizontal 
Drugs Group.
A key contribution in 2020 was the input provided to the 
Commission and the Council (the German Presidency), as 
required, on the preparation of the new EU strategy and action 
plan on drugs for 2021–2025. On 18 December the Council 
approved the EU strategy setting out the political framework 
and priorities for the EU’s drug policy in 2021–2025. The 
strategy aims to ensure a high level of health promotion, social 
Implications of COVID-19 for people who use drugs and drug service providers: in the spotlight
The public health crisis raised serious additional 
concerns relating to the well-being of people who 
use drugs; ensuring service continuity for those with 
drug problems; and protecting those offering care and 
support for this population.
What specific risks are people who use drugs likely to 
face during the COVID-19 pandemic? What services 
will they need? How will professionals working with this 
group need to adapt on the frontline? These are among 
the questions raised in an EMCDDA update published in 
March 2020, at the same time as the pandemic peaked 
in Europe.
The update was the work of an EMCDDA task force of 
experts and reviewers, which was set up to assess the 
emerging COVID-19 risks for this population and, where 
necessary, to encourage the planning and adaptation of 
frontline and specialist drug interventions.
The updates, produced in cooperation with the Reitox 
NFPs, are available in 10 EU languages.
Statement from Dianova
Dianova, an organisation consisting of an international 
network of 24 non-governmental organisations (NGOs), 
associations and foundations operating in the Americas, 
Europe, Asia and Africa, and dedicated to social change, 
made the following statement:
There has been a crucial actor in the field of drugs in 
the pandemic: the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA). The EMCDDA has 
reacted in a very proactive way, providing information 
and analysing trends in the areas of drug use, the 
provision of drug-related services and the evolution of 
drug markets …
On behalf of Dianova, we would like to thank Alexis 
Goosdeel and his team for their tireless work during the 
last months to face the pandemic by putting people at 
the centre and by supporting civil society organizations 
that work in the field of addictions.
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stability and security, to and contribute to awareness raising. 
Based on this strategy the Council will prepare an action plan 
that will set out concrete measures to achieve these priorities.
In terms of collaboration with the European Commission, 
the Director had regular meetings throughout the year with 
the Commission’s services. These included meetings with 
Commissioner Johansson, with the Director-General for 
Migration and Home Affairs, Monique Pariat, with the Deputy 
Director-General, Olivier Onidi and with the Director for Law 
Enforcement and Security, Laurent Muschel. He met on several 
occasions with Ms Floriana Sipala, Head of the Organised 
Crime and Drugs Policy Unit at DG Migration and Home Affairs. 
(See ‘EMCDDA Director: main activities’.)
Technical support was provided to the Commission in the 
NPS area, among others. Examples include the provision 
of data and technical advice on the EU common position 
to be taken on the scheduling of substances under the UN 
conventions, and on the draft delegated directives controlling 
the substances that were risk-assessed (see section above on 
the EU EWS). Information and analyses were also provided on 
other topics, such as the impact of drug trafficking from Latin 
America and the Caribbean to the EU.
In 2020 the EMCDDA continued to contribute to the 
enlargement package adopted by the Commission. The 
package contains the reports in which the Commission 
present their detailed annual assessment of the state of play 
in each candidate and potential candidate country. In 2020 
the EMCDDA provided a briefing note and a roadmap for each 
candidate and potential candidate country, assessing the 
progress and challenges met in developing a drug information 
system comparable with that in the EU. The EMCDDA also 
participated in the consultation organised by the Commission 
with the other JHA agencies.
The Commission on Narcotic Drugs (CND), the central UN 
policymaking body in drug-related matters, held its 63rd 
session in Vienna from 2 to 6 March. An EMCDDA delegation 
that included the Director and the Scientific Director attended 
the event to provide technical support to the Commission and 
the Member States, participate in a series of side events and 
make EMCDDA products available at a publications stand.
A CND special event commemorating the United Nations 
International Day against Drug Abuse and Illicit Trafficking took 
place online on 26 June. The EMCDDA Director was invited to 
give closing remarks on the impact of the COVID-19 pandemic 
on the world drug situation – the European perspective.
A workshop on cannabis took place on 6 and 7 February at 
the EMCDDA, with the participation of four other EU agencies. 
In the context of interagency collaboration, the EMCDDA met 
with the CPVO, EU-OSHA, the EFSA and the EMA to have 
a first discussion on how the different agencies dealt with 
cannabis-related technical issues within their current work 
and to share reflections about any recent developments in the 
cannabis area that were impacting their area of responsibility. 
Invited speakers from the United States (the Rand Drug 
Policy Research Center) and Canada (the Canadian Centre 
on Substance Use and Addiction) provided an overview of 
legalised recreational cannabis markets – insights from the 
Americas.
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Cannabis: in the spotlight
As of December 2019, Canada, Uruguay and several 
US states had passed laws that license the production 
and retail sale of cannabis, mostly by private companies, 
to adults for non-medical (sometimes referred to 
as recreational) purposes. With discussions about 
alternatives to cannabis prohibition becoming more 
common in some parts of the world, there is a growing 
interest in learning from the cannabis policy changes in 
the Americas.
To that end, the EMCDDA technical report Monitoring 
and Evaluating Changes in Cannabis Policies: Insights 
from the Americas was published in January. This 
report provides an overview of the changes in cannabis 
policies in the Americas and the evidence emerging from 
evaluations of their impact. Highlighting the challenges 
in monitoring and evaluating regulatory changes 
in the drugs field, it aims to respond to the growing 
interest of those involved in planning or evaluating any 
modifications to cannabis regulation.
Furthermore, an increase in the open sale of cannabis 
products in Europe has raised questions around the 
possible legal and commercial status of these products.
The new EMCDDA publication Low-THC Cannabis 
Products in Europe, released in December 2020, 
focuses on low-THC products that take forms similar 
to illicit cannabis products (e.g. smoking mixtures, oils 
and edibles (2)). The report highlights the challenges 
facing policymakers and suppliers of low-THC products, 
including the legal status of the products and the 
regulatory frameworks that may apply to their sale.
(2) Being translated into several languages (French, german and Spanish), 
with other Member States translating it too (Czechia and Poland).
FIgURe 11. Cover of EMCDDA report Low-THC Cannabis 
Products in Europe
It presents an initial overview of the situation, covering 
the types of low-THC product available, user profiles, 
associated harms and regulatory responses in Europe. 
The report provides a first overview of the EU directives 
and regulations that may be applicable to low-THC 
cannabis products in their different forms, such as foods, 
cosmetics and herbal smoking products.
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Support for drug policy in the Member States and priority 
third countries
National policymakers are one of the three key customer 
groups outlined in the EMCDDA Strategy 2025, and several 
activities were carried out by the agency in relation to this 
group in 2020.
During the year, the EMCDDA Director had high-level 
contacts with authorities in several Member States (see 
‘Business driver 4: Management’). These included meetings 
with the Delegate of the Government for the National 
Plan on Drugs, Ms Azucena Martí, the Deputy Director of 
Institutional Relations of the Government Delegation for 
the National Plan on Drugs and Head of the Spanish Focal 
Point, Ms Elena Álvarez Martín, during an official visit to 
Spain on 12 February; and an online meeting on 9 July with 
the Federal Drug Commissioner of Germany, Ms Daniela 
Ludwig, and Mr Jörg Pietsch, Head of the Office of the Drug 
Commissioner.
Furthermore, on 20 February Mr Goosdeel participated in the 
international conference on ‘Antidrug policies: prevention of 
drug phenomena and fight against drug routes – Cooperation 
strategies in the fight against drug trafficking’, organised by 
the Italian Ministry of the Interior in Rome. On that occasion, 
the Director met with Mr Giuseppe Cuchiara, Director of the 
Central Directorate for the Anti-Drugs Services of the Public 
Security Department at the Ministry of Interior. Mr Goosdeel 
also participated in the online EU National Drug Coordinators 
Meeting under Germany’s Presidency of the Council, on 
14 October, where he delivered a keynote address on harm 
reduction. The Director also spoke at the online event of the 
Cyprus National Addictions Authority on 12 November and 
participated in several events organised by the Portuguese 
authorities during the year.
The EMCDDA provided support to national policymakers 
through the evaluation of national drug strategies and action 
plans, through technical support provided upon request 
and through proactive capacity-building activities. At the 
technical level, the agency provided ongoing support to 
Portugal by evaluating the Portuguese national drug action 
plan; this included a technical meeting with the external 
evaluators responsible for the evaluation, and participating 
as an advisor in steering-group meetings. During the year, 
technical support was also provided to Cyprus for evaluation 
activities relating to their national strategy. The agency also 
organised an online workshop on policy evaluation, on 19 
and 20 November, with four IPA 7 countries. All training 
materials were updated and adapted to better fit an online 
training event.
The annual meeting of the legal and policy correspondents 
took place online on 11 and 12 June. The impact of COVID-19 
on drug policy and implementation barriers to alternatives to 
coercive sanctions were two of the topics discussed.
l Main area 2: Security
l  Drug market monitoring and identification of new trends
To support the comprehensive analytical effort in the security 
area, work continued in 2020 on improving the quality and 
availability of core supply data, in close collaboration with the 
Reitox NFPs and with our EU partner Europol.
In terms of new sources of data and innovative monitoring 
approaches, the EMCDDA, in cooperation with the Joint 
Research Centre, further developed its capacity for open-
source information and darknet monitoring, which have been 
gaining importance in understanding the rapidly evolving and 
increasingly tech-savvy drug market.
In 2020 the findings of the third joint EMCDDA–Europol 
EU Drug Markets Report 2019 and its supporting digital 
information package (which were released in November 2019) 
were disseminated widely by the EMCDDA.
This dissemination included the presentation that was given by 
the Director to the European Parliament’s LIBE Committee on 
28 January. Mr Goosdeel reiterated that the report, launched on 
26 November 2019, is a ‘clear wake-up call’ for policymakers to 
address the rapidly growing drug market, which is increasingly 
global, joined-up and digitally enabled. The Director stressed 
that the drugs problem needed to be prioritised in Europe and 
that there was no time for complacency. ‘Drugs must receive the 
attention they deserve,’ he said.
Furthermore, the EU Drug Markets Report 2019 promotional 
video, presenting highlights of the report in under four minutes, 
was produced in 10 languages: Arabic, Dutch, English, French, 
German, Italian, Polish, Portuguese, Russian and Spanish (see 
Figure 12).
The Reitox Academy on Drug Supply Indicators took 
place online on 8 and 9 October (see ‘Business driver 2: 
Partnership’). The objective of the academy was to support 
the Reitox network in the improvement of the quality of the EU 
datasets in the area of drug markets and supply. A total of 37 
participants from 24 countries attended the academy.
General Report of Activities 2020 PART I I Report of activities: key achievements of the year
26 / 78
As part of the research conducted under the EU4MD project, 
funded by the European Commission (for details, see 
‘Business driver 2: Partnership’), in November the EMCDDA 
released the report Emerging evidence of Afghanistan’s role as 
a producer and supplier of ephedrine and methamphetamine. 
This report explores whether Afghanistan, where most 
of the world’s opium is produced, has the potential to 
become a significant producer of methamphetamine, made 
from ephedrine extracted from ephedra plants grown in 
mountainous regions of Afghanistan.
COVID-19 and drug markets
The effects of the COVID-19 pandemic were also analysed by 
the EMCDDA in this area. Two rapid reports were released in 
May, shortly after the onset of the pandemic in the EU. These 
timely analyses researched the way drug markets in the EU 
adjusted to the new conditions, from the perspective of both 
supply and demand.
COVID-19 and drug markets: in the spotlight
What effect is COVID-19 having on the drug market in 
the EU?
To answer that, a new joint publication from the 
EMCDDA and Europol, EU Drug Markets – Impact of 
COVID-19, was launched on 29 May. It analysed the 
impact of the pandemic on the market for the main drug 
types (cannabis, heroin, cocaine, amphetamines, NPS), 
including demand, production, trafficking and availability.
It reported higher prices, local shortages and reduced 
purity for some drugs, while noting continued violence 
among suppliers and distributors.
It also showed how organised crime groups remain 
active and resilient, by adapting transportation models, 
trafficking routes and concealment methods, even 
during the pandemic.
The COVID-19 pandemic has also profoundly impacted 
consumers’ behaviour.
In a special report launched on 5 May, Drug Supply 
via Darknet Markets, the EMCDDA explored whether 
established methods of drug supply and distribution to 
consumers had changed during recent restrictions on 
movement.
FIgURe 13. EMCDDA–Europol joint publication
Analysing three darknet markets in the first quarter 
of 2020, the report revealed that the pandemic, and 
responses to it, appeared to have resulted in increased 
activity levels. This related mainly to cannabis, as 
‘regular cannabis users may have decided to stock up, 
anticipating market disruption during the lockdown 
period’. In contrast, as people stayed at home, the report 
pointed to a decline in the demand for drugs commonly 
used in recreational settings.
FIgURe 12. EU Drug Markets Report 2019 promotional 
video
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In 2020 the EMCDDA continued to work on drug-related 
homicide, one of the most serious manifestations of drug 
markets with a high social cost. In that regard, the EMCDDA 
released the technical report Drug-related Homicide in 
Europe: Data protocol as part of its ongoing work to develop 
and improve the monitoring of drug-related crime, harms and 
other consequences. The protocol provides a framework for 
standardised drug-related homicide data processing, which 
will allow for an improved understanding of the broader 
ramifications of drug markets and international comparisons.
l  Support policy and operational responses to drug security challenges
In the policy area, the EMCDDA provided technical input 
and advice to its key partners, in particular the European 
Commission. The analyses provided drew heavily on the 
analysis, evidence and recommendations contained in the  
EU Drug Markets Report 2019.
This included:
  support for a ‘preparatory action’ for the development of 
a tool for the monitoring and analysis of drug activity on 
darknet markets;
  input into the Croatian Presidency’s discussion paper 
on combating drug trafficking, presented at the Law 
Enforcement Working Party of the Council’s COSI;
  input, as required, into the preparation of the new 2021–
2025 EU drugs strategy and action plan on drugs, and the 
new EU security union strategy for 2020–2025.
Furthermore, the agency continued to contribute to the 
EMPACT OAPs of the EU policy cycle on organised and serious 
international crime. This included implementing the tasks 
under the OAP for 2020 and providing input into the drafting 
of the relevant OAPs for 2021 on NPS / synthetic drugs and on 
cannabis, cocaine and heroin.
Furthermore, the EMCDDA, together with its partner CEPOL, 
continued to organise and deliver training activities for law 
enforcement professionals. A total of 387 law enforcement 
professionals attended these training activities, as follows:
  188 participants in the online module on synthetic drugs;
  163 participants in a webinar on the impact of COVID-19;
  36 participants in the online training session on drug 
trafficking (postponed from 2019)
The annual meeting and proceedings of the Reference Group 
on Drug Supply Indicators took place on 27 October, via Zoom, 
due to the COVID-19-pandemic-related travel restrictions.
l Main area 3: Business drivers
l Business driver 1: Institutional
Governance and institutional developments
The EMCDDA Management Board took the unanimous 
decision on 25 June, following a proposal by the Commission, 
to renew the mandate of the agency’s Director, Alexis 
Goosdeel, for the next 5 years. Mr Goosdeel took up the post of 
Director on 1 January 2016 and will now hold the position until 
31 December 2025.
FIgURe 14. Quote from EMCDDA Director Alexis Goosdeel
Laura d’Arrigo, Chair of the EMCDDA Management Board, 
welcomed the reappointment stating:
I congratulate Mr Goosdeel on the renewal of his mandate. It 
shows the recognition by the Management Board of his vision 
for the EMCDDA and of the work accomplished under his 
guidance. The Director and his team have delivered first-rate 
results over this period, while demonstrating their ability and 
agility to adapt to unprecedented change.
As announced by the Director, the EMCDDA business model 
innovation initiative started in 2020. The objective is to 
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redesign the way the EMCDDA creates and delivers value to its 
key customers: policymakers at the EU and national levels and 
practitioners in the Member States. Work will be completed in 
December 2021, when the approach on a new business model 
will be put forward to the EMCDDA Management Board for 
adoption.
Finally, in December 2020 the EMCDDA presented to the 
Management Board the state of implementation of the 
EMCDDA’s action plan to follow up on the recommendations 
from the fourth external evaluation of the EMCDDA that was 
carried out by the European Commission in 2018, in line with 
the relevant document adopted by the Management Board in 
December 2019.
The EMCDDA in 2020: 25 years of monitoring
In 2020 the EMCDDA celebrated its 25th year of operation. 
Despite a commemorative stakeholder event being cancelled 
due to COVID-19, the project marking this milestone was able 
to deliver on the planned overall communication strategy. 
This included a monthly stream of news, content and branded 
material, disseminated via a variety of formats and channels; 
a retrospective and prospective look at the agency’s added 
value, reinforcing organisational identity; and positive 
engagement via a digital storytelling campaign, involving staff 
and key customers (see below).
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FIgURe 17. Voices campaign videos
EMCDDA Director on 25 years of monitoring
FIgURe 16. Voices video from EMCDDA Director Alexis 
Goosdeel
The EMCDDA Director said:
For the past 25 years, the EMCDDA has provided 
strategic analysis in a policy area that cuts across 
health and security. Part of the agency’s unique value 
is its comprehensive coverage of this multifaceted 
problem. By improving the comparability of drug data 
across the EU, we have given countries a ‘common 
language’ with which to describe the extent and effects 
of drug use.
We can now be proud of our internationally recognised 
European drug monitoring system, including early-
warning mechanisms to ensure rapid responses to new 
substances and emerging threats. This has contributed 
to a deeper and broader understanding of the problem, 
earning the agency the reputation as the trusted 
reference point on drugs in Europe.
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In order to mark this important milestone for the EU drugs 
monitoring, the Director launched a digital storytelling 
campaign (‘Voices’) on 26 June, the International Day against 
Drug Abuse and Illicit Trafficking. Through this campaign, and 
an internal online survey, staff members (and later external 
stakeholders from key customer groups) were invited to share 
their stories on what the EMCDDA means to them. Eight 
videos were produced and promoted via social media in the 
second half of the year, as part of this campaign.
Communication and service delivery to meet evolving 
EMCDDA customer needs
Because of the COVID-19 pandemic, 2020 also brought with it 
unusual work circumstances for the EMCDDA. In that regard, 
much of the agency’s effort was focused on adapting its work 
practices to the new conditions.
While all the EMCDDA’s operations were impacted (see 
‘Business driver 4: Management’), one key area was 
communications. On the one hand, the agency had to rapidly 
switch all of its dissemination activities online; on the other 
hand, an internal strategy had to be put in place to help 
communication with, and among, the agency’s staff who were 
teleworking. Crisis-communication activities were also carried 
out under the BCP.
In terms of external communication and dissemination, these 
continued to be guided by the EMCDDA Strategy 2025, which 
sets out a vision for a ‘healthier and more secure Europe’ 
through better-informed drug policy and action. The strategy 
states that, to do this effectively, the agency must constantly 
strive to respond to the needs of its key customers. It gives 
‘central importance to identifying our customers’ needs, 
developing services and effective communication, as these all 
represent essential elements for our work to have impact’.
The COVID-19 pandemic, however, brought with it significant 
changes in the way the world communicated in 2020; 
furthermore, it reshaped the needs of the EMCDDA’s key 
customers, namely policymakers at the EU and national levels 
and practitioners in the EU Member States. To that end, priority 
was given to ensuring that timely products and services were 
provided to these customers via the digital channels. This 
included online training courses and events (e.g. webinars – 
see ‘Main area 1: Health’ and ‘Main area 2: Security’) and 
product launches (e.g. the launch of the European Drug Report 
2020 – see ‘Main area 1: Health’ and many COVID-19-related 
products).
Furthermore, the EMCDDA’s communication efforts 
were focused on ensuring the production of high-quality 
publications – a total of 35 scientific and institutional 
publications were produced in 2020. The agency also authored 
or co-authored 29 scientific articles and book chapters.
These efforts were accompanied by activities to enhance 
engagement with the agency’s audiences, mainly via online 
communication channels (see Figure 18 for details).
This included 1 627 122 visits to the EMCDDA website during 
the year (i.e. an average of 4 500 visits per day).
Furthermore, the upward trend in the number of social media 
followers continued in 2020, with an increase observed for all 
channels (e.g. a 9 % increase in Facebook followers and a 73 % 
increase in Instagram followers).
The number of views of EMCDDA videos also rose in 2020, 
with an overall increase in lifetime views of some 30 % 
compared to 2019.
Positive engagement with the media also continued in 2020. 
The EMCDDA serviced 272 requests in the course of the year, 
down from the 378 recorded in 2019 (a slowdown possibly due 
to COVID-19) but equal to the number of requests serviced in 
2018.
More data on communications metrics can be found in 
Figure 18 and Annex Ib.
In parallel, the EMCDDA continued to implement key projects 
such as the ‘Customer needs’ project, which started in 
2018. During the year a framework for proactively identifying 
and responding to stakeholders’ needs was developed and 
prepared for testing by staff. The framework consists of 
FIgURe 18. EMCDDA online communication channels
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a collection of methods and instruments that the EMCDDA 
may use when engaging with its customers, such as customer 
journey mapping, needs and gap analyses, personas, surveys, 
online consultations, face-to-face (semi-structured) interviews, 
focus groups, workshops, metrics and staff training. Such 
methods will allow the agency to tune in to the ‘customer 
voice’, which is essential for embedding and sustaining 
customer focus and service orientation at the EMCDDA.
The next step will be to link this dynamic framework to the 
EMCDDA business model innovation initiative.
Regarding internal communication, an intranet page dedicated 
to COVID-19 was created for the agency’s staff and regular 
communications were sent in the context of the business 
continuity effort (see ‘Business driver 4: Management’). 
Furthermore, the Communication unit proposed tailor-made 
training in the design and facilitation of online events for staff, 
along with access to free online training courses to upskill in 
using a range of online platforms and tools.
l Business driver 2: Partnership
Reitox network activities
The Reitox network was set up in 1993, when the EMCDDA 
was established, and is composed of NFPs in the EU Member 
States, Norway and Turkey, as well as a focal point at the 
European Commission. The NFPs – from which the agency 
draws the bulk of its data – collect and analyse national 
information on drugs, drawing on various sectors including 
health, justice and law enforcement. They form the backbone 
of the agency’s work.
The activities of the network are defined each year in the grant 
agreement signed between each NFP and the EMCDDA, 
while longer-term strategic options are guided by the Reitox 
development framework, which was adopted by the network in 
2017.
2020 saw the completion of the first Reitox development 
framework roadmap (2017–2020), and the EMCDDA 
initiated, with input from the NFPs, an assessment of the 
implementation of this document. The results will inform the 
joint preparation of the second roadmap (2021–2025), which 
will be presented to the heads of NFPs for adoption, and to the 
Management Board for endorsement, in 2021.
Similar to other activities, work in this area was marked by 
the COVID-19 pandemic. In that regard, the EMCDDA had to 
cancel all travel to the Member States on the part of its staff, 
including any visits to the NFPs, and continue all its activities 
remotely.
This work included the two meetings of the heads of NFPs, 
which took place online on 5–7 May (62nd meeting) and 
24–27 November (63rd meeting and 9th extended Reitox 
meeting), and the two technical meetings, which also took 
place via teleconference on 10 March and 7 October.
An important means for strengthening the capacity of the 
network is provided by the Reitox academies (see also ‘Main 
area 1: Health’ and ‘Main area 2: Security’).
Two academies were organised online, as described below.
1. Reitox Academy on Drug Supply Indicators  
(8–9 October, 2 half days)
The objective of the academy was to support the Reitox 
network in improving the quality of the EU datasets in the area 
of drug markets and supply. As such, it was designed to aid the 
progress of the EU Member States, Norway and Turkey towards 
implementing the revised drug supply indicators, as developed 
by the EMCDDA, the Member States and Europol in line with 
the Council conclusions of November 2013.
A total of 37 participants from 24 countries (Austria, Bulgaria, 
Croatia, Cyprus, Czechia, Estonia, Finland, France, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, 
Spain and Turkey) attended the academy. Attendance was 
open to all relevant focal-point partners at national level, 
including – but not limited to – partners from law enforcement 
or other criminal justice agencies.
The evaluation that was carried out at the end of the event 
showed that the objectives of the academy had been met and 
that the participants were satisfied by the format and content 
of the academy.
2. Reitox Academy on the European Prevention Curriculum: 
Training for Decision-, Opinion- and Policymakers  
(26–30 October, 5 half-days)
The aim of the European Prevention Curriculum initiative was 
to implement a standardised prevention training curriculum 
in Europe and improve the overall effectiveness of prevention. 
The training curriculum was developed by the EU-funded 
project UPC Adapt, and consisted of nine units.
The academy brought together 19 participants from the 
EU Member States (Czechia, Ireland, Cyprus, Latvia, the 
Netherlands, Romania, Slovenia and Finland) and from the 
western Balkans (Albania, Bosnia and Herzegovina and 
Montenegro). Three master trainers attended the training 
course as observers (from Czechia, Spain and Portugal).
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All respondents stated that the objectives of the course had 
been met and that they gained new knowledge or skills. 
94 % expressed the view that the content was relevant to 
their professional development. Overall, the training met the 
expectation of all respondents, and there was 100 % overall 
satisfaction with the academy.
Three more academies had been planned to take place during 
the year, namely the Regional Academy on the European 
Prevention Curriculum, in Poland; the National Academy on 
Hepatitis and Drug Use, in Austria; and the Reitox Academy 
on Communication with Drug Professionals (a follow-up 
to the 2019 Reitox Academy on Communication). Due to 
the COVID-19 pandemic, however, these events had to be 
cancelled or postponed to a later stage, when conditions 
permit the organisation of on-site training.
The EMCDDA also took stock of the effects of the pandemic on 
the work of the NFPs.
EMCDDA National Focal Points’ Activities during the COVID-19 Pandemic: in the spotlight
This new EMCDDA–Reitox report highlighted how the 
network of NFPs responded to the COVID-19 crisis in 
2020. The report describes the impact of the pandemic 
on the NFPs’ work, the challenges they encountered and 
the strategies they introduced to overcome them.
The report concluded that in the course of the year 
the NFPs performed many extra activities, including 
launching new COVID-19-related surveys, creating and 
providing national guidelines, disseminating information 
to drug users and the staff of drug services and 
providing new services.
The NFPs demonstrated their great ability to adapt 
and were able to continue their work with no major 
disruptions.
FIgURe 19. EMCDDA–Reitox report
General Report of Activities 2020 PART I I Report of activities: key achievements of the year
34 / 78
To support the NFPs cope with the situation, the EMCDDA 
allowed them to use part of their 2020 grants budget to 
acquire the necessary information and communication 
technology (ICT) equipment to better cope with teleworking 
conditions, and to cover the costs of translation of COVID-19-
related reports or surveys.
Despite the pandemic, significant progress was made in 
implementing the EMCDDA Reitox certification process, 
which formally acknowledges the competence of an NFP and 
confirms that it meets the minimum criteria to fulfil the tasks of 
an NFP as set out in the EMCDDA regulation.
Certification aims to increase the legitimacy of each NFP at 
national level by demonstrating how well it contributes to the 
EMCDDA’s core tasks of collecting and reporting consistent, 
harmonised and standardised information on drugs in Europe. 
It is also designed to increase the degree of assurance at EU 
level that the NFPs are fulfilling their role as national interfaces 
with the agency. Certification covers the institutional context, 
NFP mandate, data collection, analysis and interpretation, 
reporting and dissemination. This process was described in 
the document EMCDDA Certification of the Reitox National 
Focal Points, which was published in December.
Cooperation with EU agencies
Cooperation with EU agencies continued to be strengthened 
in 2020. Key EMCDDA partners included the ECDC, the ECHA, 
the EFSA, the EMA, Europol and CEPOL.
Cooperation with the ECDC, the ECHA, the EFSA, the 
EMA and Europol took place in line with the working 
arrangements concluded with the five agencies in 2018 and 
2019 for implementing Regulation (EU) 2017/2101 of the 
European Parliament and of the Council of 15 November 
2017 amending Regulation (EC) No 1920/2006 as regards 
information exchange on, and an early warning system and risk 
assessment procedure for, new psychoactive substances (see 
‘Main area 1: Health’).
In February, the Head of Central Nervous System and 
Ophthalmology of the EMA’s Scientific and Regulatory 
Management Department visited the EMCDDA to discuss, 
among other cooperation projects, the EMA Opioid Initiative 
Taskforce and the EMCDDA’s contribution to this initiative. 
Cooperation with the EMA took place in line with Article 28(c) 
of the EU’s pharmacovigilance legislation.
Cooperation with the ECDC also took place on the subject of 
drug-related infectious diseases (see ‘Main area 1: Health’). In 
2020 the agencies began work on updating the joint guidance 
document Prevention and control of infectious diseases 
among people who inject drugs, which was initially published 
in 2011.
Joint work is also taking place on monitoring the sustainable 
development goals of eliminating viral hepatitis and ending 
the HIV epidemic. Ongoing close collaboration takes place 
through mutual participation in expert meetings and advisory 
committees of the agencies, participation in country visits at 
the request of Member States and reviews of technical reports 
(e.g. guidance on providing support for vulnerable populations 
in the EU during the COVID-19 pandemic).
Another key EU partner is Europol. In addition to their 
collaboration within the framework of the EU EWS, the two 
agencies carry out joint work within EMPACT (see ‘Main 
area 2: Security’), including collecting data on the production 
of synthetic drugs (European Reporting Instrument on Sites 
related to Synthetic Production). In 2020 the EMCDDA 
participated in four technical meetings of EMPACT.
Cooperation with CEPOL has developed, and the two agencies 
continued to organise and deliver training activities for law 
enforcement professionals (see ‘Main area 2: Security’). These 
activities were part of the EMCDDA’s contribution to the OAP 
of the COSI.
In 2020 the EMCDDA also contributed to the work of the 
JHA Agencies’ Network. During the year the nine member 
agencies initiated a dialogue to share their experiences in 
dealing with the COVID-19 pandemic and to consider new 
avenues for closer cooperation among the agencies and with 
key stakeholders inside and outside the EU. The agencies’ 
individual and joint efforts to deal with the impact of the 
pandemic were captured in a ‘Joint paper on the COVID-19 
response by the JHA agencies’, which was formally endorsed 
by the heads of the JHA agencies during a videoconference 
held on 9 July.
Throughout the year the EMCDDA contributed to the work of 
other technical networks of the EU agencies, including the 
Coordination Group on Trafficking in Human Beings, the EU 
Agencies Network on Scientific Advice, the EU Joint Taskforce 
on Artificial Intelligence, the Performance Development 
Network, the Heads of Communication and Information Network 
and the Information and Communication Technology Network.
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Cooperation with international organisations
Global organisations
The EMCDDA’s main partners at the global level are the 
UNODC and the WHO.
On a general basis, the EMCDDA contributes to technical 
discussions with the UNODC and other international partners 
on how to improve data collection and on how to facilitate 
inter-agency collaboration. The EMCDDA is also an active 
member of the international expert working group on drug 
epidemiological statistics led by the UNODC and the WHO.
Since 2014, the EMCDDA and the UNODC have collaborated 
regularly with respect to data on NPS, in line with an 
agreement from the Member States on data sharing and in the 
context of international discussions for increased cooperation 
and exchange of information on NPS (see ‘Main area 1: 
Health’). Each year, the EMCDDA provides to the UNODC Early 
Warning Advisory the list of NPS notified to the EU EWS and 
the list of the NPS seized by each EU Member State, Norway, 
Turkey and the United Kingdom.
In 2020 the EMCDDA contributed to and reviewed the 
publication The Role of Drug Analysis Laboratories in Early 
Warning Systems. This manual, published in English and 
Spanish, focuses on information available from laboratories 
analysing drug seizures or responsible for toxicological 
analysis.
The EMCDDA was also involved in the 63rd session of the 
CND (2–6 March) and the intersessional meetings of the CND 
(October). Furthermore, the EMCDDA remained in contact with 
the UNODC’s regional offices to work with non-EU countries 
on developing national drug monitoring systems and joint 
activities, such as UNODC East and South with the EU4MD 
project and UNODC for South Eastern Europe with the IPA 7 
project.
The EMCDDA cooperates with both WHO headquarters (in 
Geneva) and the WHO Regional Office for Europe.
Cooperation with WHO Europe in recent years has covered 
prison and infectious diseases, whereas cooperation with WHO 
headquarters has focused on intervention quality standards 
and the monitoring of treatment systems.
The EMCDDA, WHO Europe and the ECDC have been working 
closely to assist countries in the elimination of viral hepatitis 
in line with the WHO hepatitis elimination agenda. In January 
2020 WHO Europe, together with other leading international 
partners, attended an EMCDDA technical meeting aiming, 
through partnership and synergies at the European and 
national levels, at scaling up action on hepatitis C for people 
who inject drugs.
Cooperation with WHO Geneva also takes place in the area of 
NPS. The EMCDDA regularly assists the WHO ECDD with data 
for the prioritisation process and for the preparation of critical 
reviews. In 2020 the EMCDDA provided data to the ECDD and 
assisted it with the prioritisation of substances, which informed 
the discussions held at the 43rd ECDD meeting, which took 
place on 12–20 October.
Regional organisations
The main EMCDDA partners at regional level are the Pompidou 
Group of the Council of Europe and CICAD.
Cooperation with the Pompidou Group is based on the MoU 
signed in 2001, and annual work programmes indicate the 
core areas of cooperation. An appendix to the MoU signed in 
2010 was adopted in February 2020. The cooperation areas 
include drug policies, precursor control, prison, cybercrime, 
cooperation with non-EU countries and support for training.
Signing of the joint work programme between the EMCDDA and CICAD-
OAS (Ambassador Adam Namm, Executive Secretary of CICAD (left), and 
Alexis Goosdeel, EMCDDA Director (right)
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The EMCDDA continues to cooperate with CICAD within the 
framework of the MoU signed in October 2000 and in line with 
the new work programme for 2019–2024 that was signed 
on 21 January 2020 in Washington, during the visit of the 
EMCDDA delegation headed by Director Alexis Goosdeel. 
During the visit, Director Goosdeel met with Ambassador 
Adam Namm, Executive Secretary of CICAD. The purpose of 
the visit was to discuss ongoing EMCDDA–CICAD cooperation 
and to review the topics to be addressed under the joint work 
programme (2020–2024). The EMCDDA collaborates with 
CICAD under an MoU signed with its parent body, the OAS, in 
2000.
Strategic objectives outlined in the work programme include: 
strengthening regional and international monitoring systems; 
harmonising and developing indicators in the areas of drug 
supply and demand; supporting the establishment of national 
drug monitoring centres and drug information networks; and 
exchanging information on strategies and legislation and 
developments in drug production and use. The cooperation 
involves the EMCDDA’s participation as an observer in CICAD’s 
regular sessions and the presence of CICAD experts at EU 
expert meetings on an ad hoc basis.
Cooperation with third countries
In terms of cooperation with third countries, at the technical 
level, this was mainly carried out within the EU-funded 
technical cooperation projects IPA 7 and EU4MD (see section 
below on cooperation with third countries within the framework 
of EU-funded technical assistance projects).
At the institutional level, work was guided by the EMCDDA’s 
International Cooperation Framework, which charts the 
direction of work in this area for the 2018–2025 period, and by 
the EMCDDA Strategy 2025, which identifies partnerships as 
one of the agency’s main business drivers.
Two new working arrangements were signed in 2020, with 
Kosovo and with Serbia, via an exchange of letters between the 
EMCDDA and the respective national authorities.
The EMCDDA and Kosovo signed a new working arrangement 
on 28 September. Dignitaries attending the ceremony in 
Pristina included Agim Veliu, Kosovo’s Minister for Internal 
Affairs, Armend Zemaj, Minister for Health, and Tomaš 
Szunyog, the new EU Ambassador in Kosovo. EMCDDA 
Director Alexis Goosdeel participated in the ceremony 
virtually. The new agreement provides for the exchange of 
expertise between the entities concerned, thus contributing to 
developing drug data collection and reporting capacities in the 
region.
A working arrangement was also signed by the EMCDDA 
with Serbia, in December. Due to COVID-19 restrictions 
the agreement was formalised through an exchange of 
letters between Milan Pekić, Acting Director of the Office 
for Combating Drugs of the Government of Serbia, Prof. Dr. 
Berislav Vekić, Secretary of State at the Ministry of Health, 
Vladimir Rebić, General Police Director at the Ministry of the 
Interior, and Alexis Goosdeel, EMCDDA Director.
The working arrangements with Kosovo and Serbia follow the 
one signed in 2019 with another partner from the western 
Balkans, namely Albania, and they will pave the way for greater 
cooperation on monitoring the drug phenomenon in Europe 
and beyond.
Memoranda of understanding and working arrangements are 
also in place with the following third countries: Armenia, Israel, 
Georgia, Moldova, Russia, Switzerland and Ukraine. This allows 
the active participation of experts from the partner countries in 
EMCDDA expert meetings and the Reitox week.
Finally, an important event in the work of the EMCDDA with 
its external partners was the organisation of the ninth Reitox 
Week, which took place from 23 to 27 November. This forum 
brings together the EMCDDA’s Reitox network; representatives 
of candidate, potential candidate and neighbouring countries 
of the EU; and other key partner countries. The aims of this 
annual event are to broaden the scope of the regular meetings 
of heads of NFPs; underline the usefulness of the EU drug 
monitoring model; add impetus to the agency’s technical 
cooperation with partners outside the EU; and learn from each 
other’s experience. The 2020 Reitox Week, which took place 
virtually for the first time, brought together some 50 countries.
Cooperation with third countries within the framework of 
EU-funded technical assistance projects
Enlargement countries
Cooperation with the EU enlargement countries in 2020 mainly 
took place within the framework of the technical cooperation 
project funded by the European Commission through the IPA, 
known as IPA 7.
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The COVID-19 pandemic had a significant impact on the 
project in 2020. While some events could be organised online 
(as noted above), all of the activities involving travel (which 
represent a high proportion in a technical assistance project) 
had to be cancelled during the year. This included all the 
assessment missions and capacity building activities that had 
been planned to take place in the beneficiary countries. As 
a result, the relevant KPI was partially achieved (see Annex Ib). 
The delayed activities will be carried out in 2021 and 2022, 
depending on the evolution of the COVID-19 pandemic.
EU neighbouring countries
Cooperation with neighbouring countries took place within 
the framework of the EU4MD project, funded by the European 
Commission through the European Neighbourhood Instrument.
EU4MD: in a nutshell
Title eU4Monitoring drugs (eU4MD)
Potential beneficiaries
Algeria, Armenia, Azerbaijan, Belarus, egypt, georgia, Israel, Jordan, Lebanon, Libya, Moldova, Morocco, 
Palestine (3), Tunisia and Ukraine
Objective
To support national and regional readiness in the eNP area to identify and respond to drug-related health and 
security threats
Duration 42 months (January 2019–June 2022)
Total budget eUR 3 million
Main achievements in 2020
Knowledge exchange and capacity building:
  102 participants (from 13 countries) attended 10 capacity-building activities, including four eU expert 
meetings organised by the eMCDDA.
Reports:
  Emerging evidence of Afghanistan’s role as a producer and supplier of ephedrine and methamphetamine 
(see ‘Main area 2: Security’) (publication);
  Impact of COVID-19 on drug markets, drug use and drug-related harms and responses in east European 
neighbourhood policy countries (publication);
  Impact of COVID-19 on drug markets, drug use and drug-related harms and responses in south 
European neighbourhood policy countries (publication);
  Darknet drug-related sales in east European neighbourhood policy countries (restricted dissemination: 
Commission services, european external Action Service);
  Darknet drug-related sales in south European neighbourhood policy countries (restricted dissemination: 
Commission services, european external Action Service).
Data collection:
  COVID-19 impact on drug use, markets and services in georgia and Ukraine;
  Treatment Facility Survey ongoing in selected countries;
  work initiated to implement the 2021 european Web Survey on Drugs, drug residue analysis in waste 
water and used syringes, data collection on non-fatal drug-related emergencies and on mapping drug 
prevention systems;
  dissemination of information and visibility4 editions of eU4MD quarterly newsletter, with an audience of 
204 people at the end of 2020;
  website (in english and French);
  presence on social media.
(3) This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the Member States on this issue.
IPA 7: in a nutshell
Title
‘Stepwise integration of the IPA beneficiaries in the activities of the european Monitoring Centre for Drugs and Drug 
Addiction (eMCDDA) and the Reitox network’
Beneficiaries Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia
Objective
To enhance the capacity of the eU and the IPA beneficiaries to detect, analyse and report on emerging drug-related 
health and security threats
Duration 36 months (July 2019–June 2022)
Total budget eUR 1 million
Main achievements 
in 2020
Knowledge exchange: 35 IPA 7 experts attended four eU expert meetings organised by the eMCDDA.
Support for building eWS in selected IPA beneficiary countries: regular data exchange with eWS coordinators; 
information transmitted on NPS formally notified to IPA 7 nominated experts; information on NPS detected submitted 
regularly to the eMCDDA.
Outputs:
  impact of COVID-19 on health services and users, and on drug markets launched (for publication in 2021);
  website;
  presence on social media.
enhance data collection:
  studies launched on cannabis, methamphetamine, european Web Survey on Drugs;
  feasibility studies launched on wastewater monitoring and hospital emergency data (european Drug emergencies 
Network).
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Similar to the IPA 7 project, EU4MD was significantly affected 
by the COVID-19 pandemic, which delayed all activities for 
which travel to or from the beneficiary countries had been 
planned.
However, the project reacted very quickly to the new 
developments and carried out two trendspotter exercises to 
assess the impact of COVID-19 on the drug situation in these 
partner countries.
Impact of COVID-19 on drug markets, drug use, drug-related harms and responses in ENP countries: in the 
spotlight
The expansion of contactless drug dealing, the increase in 
the use of licit drugs and the adaptation of drug treatment 
protocols during lockdown are among the findings 
highlighted in the new EMCDDA report ‘Impact of COVID-19 
on drug markets, drug use, drug-related harms and 
responses in east European neighbourhood policy countries’.
Launched on 28 September, the report is the first 
publication released within the framework of the EMCDDA’s 
EU4MD project. The publication presents the key results of 
an EMCDDA trendspotter study, prepared in consultation 
with some 30 experts from all six eastern ENP countries.
A summary of the original English report is available in 
Azerbaijani, Armenian, Belarussian, Georgian, Romanian 
and Ukrainian.
The emergence of new drug trafficking routes, the 
reduced availability of drug-related health services and 
the adaptation of drug treatment protocols during the 
COVID-19 pandemic are among the findings highlighted 
in the report ‘Impact of COVID-19 on drug markets, 
drug use, drug-related harms and responses in south 
European neighbourhood policy countries’.
The report, released under EU4MD, presents the key 
results of an EMCDDA trendspotter study, prepared in 
consultation with some 20 experts from seven southern 
ENP countries.
A summary of the original English report is available in 
Arabic, French and Hebrew.
In 2020 the EMCDDA was also granted funding of 
EUR 800 000 by the European Commission to implement 
a project with Georgia. The new project, called EMCDDA4GE, 
will start in 2021, with a duration of 24 months.
Other events with partners
In 2020 the implementation manual Early Warning System on 
new psychoactive substances & emerging drug phenomena 
was published by the Cooperation Programme between Latin 
America, the Caribbean and the European Union on Drugs 
Policies (Copolad II). The EMCDDA contributed to the revision 
of this manual and was one of its editors.
On 26 June the EMCDDA was joined by a range of its external 
partners in a virtual event following on from the International 
Day against Drug Abuse and Illicit Trafficking. The meeting 
was a symbolic gathering of representatives of the European 
Commission, the permanent missions representing the partner 
countries in Brussels, the delegations of the European Union in 
these countries and the partner countries’ national correspondents.
Reflecting the theme for this year’s international day – ‘Better 
knowledge for better care’ – EMCDDA Director Alexis Goosdeel 
delivered a keynote speech on lessons learned regarding the 
impact of COVID-19 on the drug situation in Europe.
l Business driver 3: Scientific capacity
Scientific Committee activities
As the guardian of the EMCDDA’s reputation for scientific 
excellence, the Scientific Committee plays a key role in 
ensuring and improving the quality of the work carried out by 
the agency.
In January the EMCDDA’s newly appointed Scientific 
Committee embarked on its 2020–2022 mandate, following its 
official appointment by the Management Board in December 
2019.
During the year, the Committee – composed of 15 high-
level scientists selected from the EU Member States, 
Norway and Turkey – adopted a formal opinion on the 
EMCDDA’s Single Programming Document 2021–2023, 
and provided input on the agency’s main projects and 
scientific publications, in line with the guiding principles 
for the review of selected publications. The Scientific 
Committee also contributed to the Horizontal Drugs Group’s 
annual dialogue on research.
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Prof. Dr. Catherine Comiskey, Chair of the EMCDDA Scientific Committee
The Committee’s 52nd meeting took place virtually on 
13 November, when Prof. Dr. Catherine Comiskey (Ireland) was 
elected to the position of Chair and Prof. Dr. Henri Bergeron 
(France) to the position of Vice-Chair for 2020–2022.
In 2020 the Committee continued to make a significant 
contribution to upholding the agency’s scientific integrity, 
covering the most relevant scientific fields linked to the 
problems of drugs and drug addiction today.
The EMCDDA Data Quality Board approved the roles and 
responsibilities within the framework of its Data Quality 
Management Framework and the new terms of reference for 
the Data Coherence Group, two important tools for further 
developing the scientific quality of EMCDDA’s outputs and 
services. These initiatives also completed the follow-up plan on 
the recommendations of the 2017 Internal Audit Service (IAS) 
audit of the management of data and the respective action 
plan.
The Lisbon Addictions Programme and Organising Committee, 
which the EMCDDA co-chairs, met throughout the year to 
assess the impact of COVID-19 on the organisation of the 
Lisbon Addictions conference. After a careful assessment 
of all the implications, the next edition was postponed to 
November 2022, and the two committees started working 
on the reconceptualisation of the conference and necessary 
preparatory activities.
Finally, in 2020, the new committee also assessed the risks 
of three NPS (see ‘Main area 1: Health’). This is one of the key 
roles of the committee. On the basis of the risk assessments 
the Commission decided to control all three substances in the 
EU.
l Business driver 4: Management
EMCDDA Director: main activities
The Director, through his external activities, contributed to 
increasing the visibility of the EMCDDA and consolidating the 
credibility of its work by building and improving partnerships. 
Some examples are listed below.
The purpose of these activities was twofold: to provide 
information on the performance of the EMCDDA in delivering 
on its mandate and implementing its annual work programme; 
and to communicate the scientific evidence resulting from the 
agency’s monitoring and analytical work.
These high-level communication efforts, which involved 
some missions at the beginning of 2020 and the Director’s 
participation in online events after mid March, were focused on 
the agency’s key customers, namely drug policymakers at the 
EU and national levels and practitioners working in the field. 
Important institutional exchanges also took place with high-
level representatives of some international organisations and 
third countries.
EU bodies
In terms of EU policymakers, Mr Goosdeel further strengthened 
relationships with the European Parliament. The Director 
gave presentations at three meetings of the European 
Parliament’s LIBE Committee. On 28 January he presented 
the joint EMCDDA–Europol EU Drug Markets Report 2019, 
together with a Europol representative. On 4 June the Director 
gave an overview of the impact of the COVID-19 pandemic 
on the drugs situation, and on 27 October he presented the 
main findings of the European Drug Report 2020 – Trends 
and developments, remotely, to the members of the LIBE 
Committee. In addition, throughout the year he had meetings 
with several members of the European Parliament on issues 
concerning the work of the agency and budgetary needs for 
2021.
Concerning the Council, on 21 February the Director 
participated in a meeting of the Council’s COSI in Brussels.
The Director had regular meetings with the European 
Commission’s services throughout the year. These included 
meetings with Commissioner Johansson, the Director-
General of DG Migration and Home Affairs, Monique Pariat, 
the Deputy Director-General, Olivier Onidi, and with the 
Director for Law Enforcement and Security, Laurent Muschel. 
He met on several occasions with Ms Floriana Sipala, Head of 
the Organised Crime and Drugs Policy Unit at DG Migration 
and Home Affairs. On 29 September the Director participated 
in a videoconference meeting with Commissioner Johansson 
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and Ms Pariat. The meeting was organised between DG 
Migration and Home Affairs and the directors of six home 
affairs agencies (EASO, the European Border and Coast 
Guard Agency (Frontex), the EMCDDA, Europol, CEPOL and 
eu-LISA) to establish a forum for joint strategic reflection, 
the exchange of information and coordination on matters of 
common interest. On 26 October the Director participated in 
the informal workshop organised by DG Migration and Home 
Affairs by videoconference for the EMCDDA Management 
Board members on the revision of the EMCDDA’s mandate. 
The meeting was chaired by Mr Laurent Muschel, Director for 
Law Enforcement and Security.
With regard to building relationships with the other EU 
agencies, Mr Goosdeel participated in the meeting of heads 
of EU agencies on 6 February in Brussels, and the one on 
8 October by videoconference. The Director also participated 
in virtual meetings of the heads of JHA agencies, on 9 July and 
20 November, and attended an extraordinary online meeting of 
heads of EU agencies on Brexit with the Commission’s UK Task 
Force on 26 November.
EU Member States
The Director paid an official visit to Spain on 12 February 
2020. The visit included meetings with the Delegate of the 
Government for the National Plan on Drugs, Ms Azucena 
Martí, the Deputy Director of Institutional Relations of the 
Government Delegation for the National Plan on Drugs 
and Head of the Spanish Focal Point, Ms Elena Álvarez 
Martín, and other members of the Executive Committee 
of the Government Delegation for the National Plan on 
Drugs. Meetings were also organised with representatives 
of the International and Ibero-American Foundation for 
Administration and Public Policies to discuss the EMCDDA’s 
cooperation within the Copolad, Central Asia drug action 
programme and EU action against drugs and organised crime 
projects. Finally, the Director visited the Intelligence Centre 
for Counter-Terrorism and Organized Crime and met with the 
Director, Mr Ángel Alonso.
On 20 February Mr Goosdeel participated in the international 
conference on ‘Antidrug policies: prevention of drug 
phenomena and fight against drug routes – Cooperation 
strategies in the fight against drug trafficking’, organised by 
the Italian Ministry of the Interior in Rome. On that occasion, 
the Director met with Mr Giuseppe Cuchiara, Director of the 
Central Directorate for the Anti-Drugs Services of the Public 
Security Department at the Ministry of Interior.
The Director had an online meeting on 9 July with Ms Daniela 
Ludwig, the Federal Drug Commissioner of Germany, and 
Mr Jörg Pietsch, Head of Office of the Drug Commissioner. 
Mr Goosdeel participated in the online EU National Drug 
Coordinators Meeting under Germany’s Presidency of the 
Council on 14 October. The meeting focused on people-
centred drug policies, with a special emphasis on vulnerable 
groups, and explored the topics of prevention, early 
intervention and harm reduction. Mr Goosdeel delivered 
a keynote address on harm reduction at the meeting.
The Director spoke at the Cyprus National Addictions Authority 
online event on 12 November.
An online meeting between the Director and the Belgian 
Minister for the Interior, Ms Annelies Verlinden, took place on 
7 December to discuss the budget for EMCDDA and priorities 
within drug-related policies.
Mr Goosdeel participated in several events organised by the 
Portuguese authorities.
International organisations and third countries
Mr Goosdeel paid a technical visit to the United States on 
20–24 January. He met with Ambassador Adam E. Namm, 
Executive Secretary of CICAD. Mr Goosdeel had a meeting 
on 22 January with Director James W. Carroll of the Office of 
National Drug Control Policy, and on 23–24 January visited the 
headquarters of the Drug Enforcement Administration (DEA) 
and its Special Testing Laboratory.
Visit by the EMCDDA delegation headed by EMCDDA Director Goosdeel at 
the Drug Enforcement Administration’s Special Testing Laboratory.
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The Director participated in the 63rd session of the CND, 
on 2–4 March, organised by the UNODC in Vienna. On 
3 March Mr Goosdeel gave a presentation entitled ‘25 years 
of supporting evidence-informed policies and actions in the 
EU – the EMCDDA approach’ at the Croatian side event on 
‘Comprehensive and evidence-based approach in tackling 
the world drug problem’. On the same day, Mr Goosdeel 
participated in a European Union side event with a joint 
presentation of the EU Drug Markets Report 2019, together 
with a representative from Europol.
He delivered a keynote speech on 4 June at the online 
Copolad II Final Conference.
On 26 June the Director participated by videoconference 
in a special commemorative event of the 63rd session of 
the Commission on Narcotic Drugs, on the occasion of the 
International Day against Drug Abuse and Illicit Trafficking 
organised by the UNODC. During this event the World Drug 
Report 2020 was launched, followed by a discussion on the 
impact of the COVID-19 pandemic on the world drug situation, 
from a regional perspective, co-sponsored by the European 
Union and the UNODC. The Director made the closing remarks.
EMCDDA operational response to the COVID-19 pandemic
On 11 March the WHO declared coronavirus disease 2019 
(COVID-19) a pandemic. As a result, and following the 
guidelines issued by the Portuguese authorities, the EMCDDA 
Director decided to activate the BCP on 13 March (Friday), at 
midnight. As of the next working day (16 March), the agency’s 
staff switched to teleworking mode.
In a statement informing employees on 13 March, the Director 
stressed that:
The decision to switch to teleworking has been taken to 
strengthen efforts to protect EMCDDA staff and their families. 
But it has also been taken in the spirit of our common 
responsibility to help flatten the curve of infection and ease the 
pressure on national healthcare systems.
He then added:
This is a very unusual moment, both for the EMCDDA and for 
the EU and its citizens, and we will only be able to cope with 
the current situation by remaining united and solidary.
This decision was the latest in a number of proactive 
contingency measures taken by the EMCDDA’s management 
since late February, the beginning of the COVID-19 outbreak 
in Europe, in line with the scientific evidence published by the 
ECDC, the WHO, the Portuguese health authorities and its 
own medical adviser. These measures, which were aimed at 
minimising the risk of infection, included postponing meetings, 
cancelling work trips, limited access to the premises and 
quarantining a small number of staff members due to recent 
travel history.
In preparation for the shift, staff members were trained in the 
technical skills required for an extended teleworking period 
and advised on how to adapt work methods and procedures in 
the new circumstances.
In addition to the staff teleworking, key measures of the BCP 
included the following.
  Weekly meetings of the Incidence Response Team, 
consisting of the Director, the business continuity 
manager, the agency’s medical adviser and other key staff. 
During these meetings the situation at the EMCDDA and 
in Portugal was analysed, and updates were then sent to 
all the agency’s staff.
  Establishing clear protocols and procedures for accessing 
the EMCDDA premises and for communicating on COVID-
19-related events. These procedures were kept updated 
and published on a dedicated intranet page, including 
a section on questions and answers.
  Intensifying the internal communication effort, including 
regular staff updates on the situation by the Director, the 
business continuity manager and the agency’s medical 
adviser.
  Redefining the workflows in some key areas (e.g. 
finance) in order to adjust to the switch of the operations 
concerned from paper-based to fully electronic work 
circuits.
  Ensuring that the ICT infrastructure would support the 
organisation’s teleworking efforts (see later section under 
this business driver).
While these measures were initially designed to last for 
a limited period (a few weeks), the evolution of the pandemic 
has obliged the EMCDDA, like other organisations, to maintain 
its BCP for a much longer time (at the time this report was 
drafted, in March 2021, the BCP was still active and the 
EMCDDA continued to function in teleworking mode).
Data-protection activities
Regulation (EU) 2018/1725 on data protection was fully 
observed during the year, and the activities required, in 
particular regarding data protection records, were carried out. 
Furthermore, the EMCDDA Management Board approved, 
in its meeting in June, a decision on a review of the internal 
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rules concerning the processing of personal data within the 
framework of the EMCDDA’s operation.
Strategic planning and corporate performance monitoring 
and reporting
The EMCDDA ensured the efficient implementation of the 
annual work programme, which is part of the Programming 
Document 2020–22. The agency achieved 95 % of the results 
defined in the work programme as level-1 priorities, 74 % of the 
level-2 priority results and 43 % of the level-3 priority results 
(see Annexes Ia and Ib).
While, due to the COVID-19 pandemic, the initial targets (4) 
were not met, the EMCDDA showed not only its resilience in 
continuing its work without interruption, but also its agility in 
adapting to the new situation and changing its work priorities 
accordingly. As a result, the agency was highly responsive in 
providing its key customers with timely information, including 
on the impact of the pandemic on drug use, drug harms and 
drug markets in the EU. Projects that were no longer a priority 
in the given conditions were put on hold in 2020, while 28 new 
projects were kicked off, 11 of which were related to COVID-19.
This was accompanied by a subsequent reallocation of 
the agency’s resources that made possible a significant 
investment in the new priorities, the most important of which 
was the procurement of ICT equipment (the workstations 
transformation programme – see later section under this 
business driver).
In terms of planning, the next single programming 
documents – for 2021–2023 and 2022–2024 (preliminary 
draft) – were also delivered in a timely manner to the 
EMCDDA’s stakeholders, and both documents were adopted 
by the Management Board in December 2020.
Concerning corporate reporting, the main output was the 
General Report of Activities 2019, which was adopted by the 
EMCDDA Management Board through a written procedure, 
and was published on 15 June.
Finally, 2020 brought a new approach to operational planning, 
monitoring and reporting at the EMCDDA. Despite the 
challenges related to the teleworking conditions under the 
pandemic, the agency managed to successfully roll out its 
new management information system – the Matrix@EMCDDA 
project. Matrix is the application that now supports the 
EMCDDA’s internal management plan.
(4) ‘KPI 7: Work programme delivery’ had set up the following targets: 100 % of 
level-1, 80 % of level-2 and 50 % of level-3 outputs/results achieved.
As part of the change management component of this 
important corporate project, the EMCDDA also changed its 
performance monitoring process: quarterly performance 
reviews were established, carried out in Matrix, to replace the 
previous mid-year performance review exercise.
While its roll-out involved considerable resources, mainly in 
terms of staff time, the new system centred on Matrix has 
also brought increased reliability, stability and transparency 
in implementing work programme monitoring at the 
EMCDDA. Further improvements are envisaged with a view 
to enhancing the user experience and system operability and 
functionality.
Financial resource management
The priorities in the field of financial resources management 
were effective and timely planning, monitoring and execution 
of the EMCDDA budget, and optimising all of the related 
processes. These were complemented by the efficient use of 
material resources. In this context, the EMCDDA reached the 
maximum level of performance in terms of budget execution, 
with 100 % of commitment appropriations executed (see 
Table 1). In terms of procurement execution, the procurement 
plan was put in place and successfully executed in close 
collaboration with all units.
TABLe 1. Budget execution
Commitment appropriations 100 %
Payment appropriations 94.73 %
Consumption of 2020 (C8) credits 91.55 %
Human resources management
The sound management of existing processes, as required by 
the applicable Staff Regulations and their implementing rules, 
remained key in 2020.
Another priority was the organisation of appropriate training 
for the agency’s staff, to support the effective implementation 
of the EMCDDA’s new long-term strategy. The target of 
providing an average of 3 training days per staff member (KPI 
2.3; see Annex 1b) was only partially achieved pursuant to the 
exceptional constraints entailed by the COVID-19 pandemic, 
because of which several actions for initially planned training 
sessions had to be cancelled/reconsidered due to force 
majeure, and were only partially replaced by available actions 
for online/remote training.
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Facility support services
In the area of logistics and infrastructure management, 
ensuring a healthy and safe working environment remained key 
in 2020.
To that end, the identification of health and safety risks for 
staff remained one of the main priorities of the agency, as did 
increasing effectiveness, efficiency gains and cost savings, 
including through further synergies with the European 
Maritime Safety Agency (EMSA). The information included 
in the risk registry was adapted following the annual risk 
assessment exercise that was delivered in 2020.
The agency also implemented further measures to guarantee 
the efficient use of the EMCDDA’s infrastructure, with special 
attention paid to controlling utility-related costs, building 
possible further synergies with EMSA and ensuring a safe 
working environment. In this respect, it is worth noting that, 
compared to 2019, the agency managed a reduction of 10.4 % 
in utilities costs during 2020.
In line with the policy in place at the EMCDDA, this was 
complemented by environmentally friendly measures (an 
internal environmental report was delivered in 2020 – see 
Annex VII).
Information and communication technology support 
services
The EMCDDA’s ICT programmes and services are developed 
and delivered in line with the triennial objectives, which 
are to implement and support core business and corporate 
projects and processes and to provide a continuously stable 
environment that supports existing basic and advanced 
services.
Concerning providing support for core business areas, the 
priority in 2020 was to respond to the important changes 
in the organisation of work brought about by the COVID-19 
pandemic.
To that end, ICT operations during the year concentrated 
on ensuring that the specific needs of the BCP could be 
fulfilled. Furthermore, and looking at the future, the EMCDDA 
has accelerated the initiation of the EMCDDA workstation 
transformation programme, which aims to create a modernised 
digital workplace that will enable the agency’s staff to make full 
and efficient use of teleworking as an increasingly established 
work practice.
The optimal allocation and prioritisation of ICT resources was 
supported by the internal ICT Steering Committee, by refining 
priorities and deciding on the intensity of work to be devoted 
to each activity, depending on the most critical organisational 
needs.
Synergies and efficiency gains
Synergies with EMSA were further pursued in the areas of staff 
training, infrastructure management and ICT.
II




l 2.1. Management Board
l Main decisions
As usual the Management Board met twice during the year, but 
the meetings were held for the first time by videoconference 
due to the COVID-19 pandemic. The first meeting took place on 
24 June and the second on 10 December 2020.
At the June meeting the Management Board held an exchange 
of views on the impact of the COVID-19 pandemic on the 
drugs situation. The Director presented highlights from the 
EMCDDA’s budgetary and financial performance, along with 
the main achievements of the EMCDDA in 2019 based on the 
General Report of Activities. The Management Board adopted 
a favourable opinion on the EMCDDA’s final annual accounts 
for 2019 and congratulated the Director and his staff on the 
excellent budgetary execution.
The Management Board agreed with the Working Arrangement 
between the EMCDDA and the Ministry of Internal Affairs and 
Public Administration and the Ministry of Healthcare of Kosovo 
and mandated the Director to sign the arrangement at a date 
and place to be jointly decided.
In restricted session, the Management Board decided 
unanimously, following a proposal by the Commission, that 
the term of office of Mr Alexis Goosdeel as Director of the 
EMCDDA would be extended for a duration of 5 years, with 
effect from 1 January 2021.
At its 62nd meeting on 10 December 2020, the Management 
Board held an exchange of views on ‘Developing capacity 
building on prevention in the EU’. As usual at the December 
meeting, the Management Board adopted the EMCDDA’s 
budget for 2021 and preliminary draft budget for 2022.
In line with the provisions of Article 32 of the framework 
financial regulation applicable to EU agencies and of the 
EMCDDA financial regulation, the Management Board adopted 
the EMCDDA’s Single Programming Document 2021–2023, 
including the 2020 work programme. The board also adopted 
the EMCDDA’s preliminary draft programming document 
for 2022–2024, which includes the preliminary draft work 
programme for 2022.
In restricted session, the Management Board elected Ms Elina 
Kotovirta (Finland) as an Executive Committee member, with 
a mandate running from 1 January 2021 to 31 December 
2023. The Management Board also decided that Mr Alexis 
Goosdeel, Director of the EMCDDA, would be assigned to 
a post of grade AD 15, as available in the EMCDDA authorised 
establishment plan, with effect from 1 January 2021.
The Management Board approved the implementation by the 
EMCDDA of a project for technical assistance to Georgia.
l 2.2. Major developments
The COVID-19 pandemic was a major external factor that 
significantly influenced the work of the agency as of mid March 
2020 (for details see Part I of this report and Annexes Ia and 
Ib).
The EMCDDA showed great flexibility in adapting swiftly to 
a 100 % teleworking and videoconferencing mode. Despite 
the challenge of these unprecedented circumstances, the 
new working methods allowed the EMCDDA to continue 
implementing its activities and delivering its services in line 
with the emerging needs of its key customers.
To that end, the agency created a task force to design a series 
of new products on the impact of the pandemic on drug 
users and professionals in the drugs field, based on almost-
real-time reporting. While some of the projects that had 
been planned prior to the pandemic had to be deprioritised, 
the EMCDDA released new resources and disseminated 
knowledge in innovative ways, reaching an increased number 
of stakeholders.
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l  2.3. Budgetary and financial management
Information on budgetary and financial management is 
provided by the report included in the EMCDDA’s Annual 
Accounts 2020 (see Annex VIII).
In terms of procurement execution, the 2020 procurement plan 
was put in place in line with the EMCDDA 2020 management 
plan, and was successfully executed in close collaboration with 
all units.
The negotiated procedures launched during the course of the 
year are outlined in the tables below.
TABLe 2. EMCDDA negotiated procedures in 2020




Negotiated procedures – see Annex I, Section 11.1(a) of the financial regulation 
applicable to the general budget of the Union (exceptional procedures)
0 0 0
Negotiated procedure – single tender (*) 95 95 0
Negotiated procedure – at least three candidates 7 6 1
Negotiated procedure – at least five candidates 5 4 1
Open procedures 4 1 3
European Commission frameworks joined 6 0 6
(*) Including appointment letters and very-low-value contracts.
TABLe 3. EMCDDA negotiated procedures’ values in 2020





























5 11 338 7 22 314 83 623 036 95 89 % 656 688 50 %
eUR > 15 000
and ≤ 60 000




0 0 0 0 5 402 572 5 5 % 402 572 30 %
Total 5 11 338 7 22 314 95 1 291 209 107 100 % 1 324 860 100 %
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l  Summary of budgetary operations, revenue and expenditure
The information about the appropriations transferred in 
2020 can be found in the report on budgetary and financial 
management, as included in the EMCDDA’s Annual Accounts 
2020. The EMCDDA Management Board approved two 
amending budgets in 2020, which were duly published.
The results achieved under the main financial/performance 
indicators for 2020 are 100 % execution of commitment 
appropriations, 94.73 % implementation of payment 
appropriations, 91.55 % execution of appropriations carried 
forward from 2019 and 0.65 % cancelled/unused payment 
appropriations.
l  Information on grants, contribution and service-level agreements
Pursuant to the decision taken by the relevant EU authorities, 
in 2020 the EMCDDA received EUR 1 007 367 from the EU 
budget as the second instalment of EU financing for the second 
year of execution of the EU4MD project (for more details, see 
‘Business driver 2: Partnership’). This technical assistance 
project aims at enhancing the capacity of eastern and southern 
ENP countries (it can also cover, on an ad hoc basis, the 
‘neighbours of the neighbours’) to monitor drug markets and 
contribute to improving national and regional responses to 
security and health-related threats posed by contemporary drug 
markets and related issues. The project concerns the following 
beneficiary countries: Algeria, Egypt, Israel, Jordan, Lebanon, 
Libya, Morocco, Palestine and Tunisia (for the southern 
neighbourhood partnership); and Armenia, Azerbaijan, Belarus, 
Georgia, Moldova and Ukraine (for the eastern neighbourhood 
partnership). The project will run from 1 January 2019 to 
30 June 2022, and the appropriations allocated from the EU 
budget for its execution amount to a total of EUR 3 000 000. 
In accordance with the relevant financing agreement, these 
appropriations are provided by annual instalments, to be 
entered into the EMCDDA budget as assigned appropriations.
Concerning service-level agreements (SLAs) concluded by the 
EMCDDA, the following were in force in 2020:
  SLA between the EMCDDA and the European Commission 
(DG for Human Resources and Security) for the provision 
of services (upon agreed compensation whose amount 
depends on the actual services provided) relating to staff’s 
training, health/medical services, safety and security;
  SLA between the EMCDDA and the European Commission 
(Office for the Administration and Payment of Individual 
Entitlements) for the provision of services (upon agreed 
compensation whose amount depends on the actual 
services provided) relating to the management of staff’s 
pecuniary rights;
  SLA between the EMCDDA and the European Commission 
(DG Budget) for the provision of services (upon agreed 
compensation whose amount depends on the actual 
services provided) relating to the use of the electronic 
management and accounting system (ABAC) system;
  SLA between the EMCDDA and the European Commission 
(DG Informatics) for the provision of services (upon 
agreed compensation whose amount depends on the 
actual services provided) relating to the hosting of the 
ABAC, ICT procurements, e-procurement (e-Prior services) 
and secure connectivity/access to Commission-hosted 
applications (Rachel);
  SLA between the EMCDDA and the European Commission 
(DG Informatics) for the provision of services by the EU 
Computer Response Team – CERT EU – relating to ICT 
security (computer emergency response);
  SLA between the EMCDDA and EMSA relating to the 
shared management of the premises of their headquarters 
and the sharing of the associated services and costs;
  SLA between the EMCDDA and EMSA relating to 
synergies for the sharing of ICT services and equipment.
Further information can be found in Annex VI.
l  2.4. Delegation and sub-delegation of the powers of budget implementation to the agency’s staff
The EMCDDA has set its internal procedures for budget 
execution and internal control while defining and implementing 
a partially decentralised management model, in accordance 
with the EMCDDA financial regulation, which transposes in 
its entirety the text of Commission Delegated Regulation (EU) 
No 2019/715 on the framework financial regulation for EU 
agencies.
As a consequence, both the operational and the financial 
decisions required for the implementation of the EMCDDA’s 
single programming document and budget have been 
delegated to the heads of unit. The administration unit provides 
support to managers for budgetary and financial management 
execution and the implementation of financial transactions, as 
well as for internal budget planning, monitoring and reporting.
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These procedures have been codified, and all of the EMCDDA’s 
deputy authorising officers have received specific training and 
information on their roles, duties and liabilities, in accordance with 
the provisions of financial regulation and the Staff Regulations.
The key actors in and steps of the EMCDDA’s procedures for 
budget execution can be summarised as follows (see also 
Tables 4 and 5 below).
  Project manager: initiates and provides operational input 
for the administrative and financial operations related to 
project implementation (e.g. technical specifications for 
procurement procedures, cost estimates and ‘certified 
correct’ for payments).
  Budget and financial management team: undertakes budget 
planning and monitoring, checking for consistency with the 
programming document and budget allocations. Financial 
and contractual support officers provide assistance in the 
preparation of administrative and contract documents with 
the input of the project manager involved.
  Financial management: initiating officers carry out 
operations using the EMCDDA’s ABAC system, prior to 
decisions of the authorising officer.
  Executive office unit: the verifying officer carries out ex 
ante financial verification.
  Accounting officer: executes and records payments and 
recovery orders.
The procedures presented above are consistent with the 
EMCDDA’s project-based working methods, which aim to 
integrate activity and resource management, in accordance 
with activity-based management / activity-based budgeting 
principles. In this context, the EMCDDA has established 
procedures for planning, monitoring and reporting, with 
a clear indication of the actors involved, their roles and their 
responsibilities.
After the adoption of the new ‘Operating framework for the 
Reitox system’ in January 2003, a new grant agreement model 
was introduced for the annual co-financing of activities by 
the Reitox NFPs. According to this agreement an external 
audit may be carried out each year by an independent body 
or expert, in order to certify that any financial documents 
submitted to the EMCDDA comply with the financial provisions 
of the agreement, that the costs declared are the actual costs 
and that all receipts have been declared.
TABLe 4. Key features of the EMCDDA’s partially decentralised management mode
Level of operations (and actors) Role/operations
Decentralised level (operational 
and technical units)
Operational initiative/input and operational and financial decisions by delegation in order to implement the 
work programme and budget
Central level (executive office 
unit and administration unit)
Coordination and management of executive planning, monitoring, reporting and assessment of the 
implementation of the work programme and budget. Administrative and financial support, management and 
control of implementation
TABLe 5. Key actors involved in implementing the EMCDDA’s partially decentralised management model
Level of operations Actors Role/operations
Decentralised level 
(operational and technical 
units)
Project manager and head of 
the unit concerned
Initiates and provides operational input into the operations required to 
implement projects
Decentralised level 
(operational and technical 
units)
Project manager and head of 
the unit concerned
Initiates and provides operational input into the operations required to 
implement projects
Central level (administration 
unit)
Budget planning and 
monitoring team
Checks the consistency of operations with the adopted work programme 
and budget. Budgetary appropriations to be committed are set aside
Human resources 
management team
Defines rights and checks compliance with Staff Regulations for staff-
related management and expenditure
Financial management team
Prepares the required administrative and legal supporting documents, 
controls compliance with applicable regulations and processes the required 
financial operations
Central level (executive office 
unit)
Verifying officer Ex ante verification
Decentralised level 
(operational and technical 
units)
Head of unit / deputy 
authorising officer
Authorises budgetary and legal commitments and payments
Central level (administration 
unit)
Accounting officer executes and records payments and recovery orders
General Report of Activities 2020 PART IIA I Management
49 / 78
In order to effectively tackle the exceptional constraints 
entailed by the pandemic COVID-19 and meet the need to 
operate remotely in this context, as from 16 March 2020, and 
until further instruction, the process for the management of the 
EMCDDA financial operations has been digitalised as much as 
possible and concentrated in a reduced number of financial 
actors, in line with the chain of command of the EMCDDA 
authorising officer.
The EMCDDA’s activities and operations are scrutinised by 
several processes and actors:
  external audits by the European Court of Auditors (ECA) 
(twice a year);
  external audits for specific projects (IPA-funded projects 
etc.);
  discharges by the European Parliament (once a year);
  internal audits by the IAS of the European Commission 
(once a year);
  opinions of the European Commission’s services on the 
agency’s programming document (once a year);
  external periodic evaluations (set at every 6 years in the 
EMCDDA founding regulation);
  agreements by the European Commission on 
implementing rules for the Staff Regulations (one 
agreement for each rule);
  consent by the European Commission on the possible 
deviation of the EMCDDA financial regulation from 
the Commission’s framework financial regulation for 
decentralised agencies;
  the European Data Protection Supervisor, for compliance 
with Regulation (EC) No 45/2001 (by prior notification and 
upon complaint);
  the European Anti-Fraud Office (upon complaint);
  the Ombudsman (upon complaint);
  the Court of Justice of the European Union (upon 
complaint).
Ex ante controls of financial transactions were applied 
exhaustively throughout 2020 to verify their compliance with 
the EMCDDA financial regulation and the corresponding 
implementing rules. These controls were carried out swiftly to 
ensure that payment deadlines were met, legal commitments 
were concluded in a timely manner and income was recovered 
promptly, without prejudice to the application of corrections, if 
required.
Financial workflows were properly defined and a sound system 
of authorisation of access to the ABAC was put in place. The 
manual of procedures was applied and updated, as required.
l 2.5. Human resources management
l Human resources developments
The work to align the EMCDDA’s human resources processes 
and policies with the reform of the EU Staff Regulations 
continued in 2020. This included, in particular, the adoption 
of implementing rules on the duties of Commission drivers 
(Decision C(2019) 7822), on leave (Decision C(2020) 1559) 
and on the transfer of pension rights (Decision C(2020) 4818). 
As in previous years, the EMCDDA participated in the work 
carried out by inter-agency working groups in this area.
As regards the EMCDDA 2020 establishment plan, the total 
number of authorised posts was equal to that in the EMCDDA 
establishment plan for 2019 (i.e. 76 posts), pursuant to the 
relevant decision of the EU budget authority.
l  Brief description of the results of the screening/benchmarking exercise
The results of the EMCDDA 2020 staff screening exercise 
reflect the EMCDDA’s efforts to ensure the effective and 
efficient allocation and use of its resources (see Annex IV). The 
results show that 72.24 % of the EMCDDA’s human resources 
capacity was devoted to operational activities in 2020 and 
only 18.25 % was allocated to administrative support and 
coordination; the remaining 9.50 % was assigned to operations 
considered neutral.
l 2.6. Strategy for efficiency gains
As far as efficiency gains are concerned, and as they result 
from the EMCDDA’s past and present performance in the 
use of assigned resources, the EMCDDA is committed to 
constantly improving the effectiveness and efficiency of its 
activities and to maximising the use of its resources. In this 
context, the EMCDDA has pursued action to further rationalise 
and reduce the running costs of its premises – namely through 
measures aimed at reducing energy consumption – to offset 
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the impact of the extension of staff working time pursuant to 
the entry into force of the revised Staff Regulations (e.g. by 
installing solar shading on glass areas, solar power panels, 
climate-control switches on windows and an intelligent lighting 
system, or by optimising heating and cooling cycles at the 
EMCDDA’s premises).
Cooperation and synergies with EMSA have been intensified 
beyond those resulting from the implementation of the 
agreement in force between the two agencies to share the use 
of common areas in the compound where their headquarters 
are located (namely the canteen, underground parking area 
and conference facilities). Further cooperation and synergies 
have been developed, in a common effort to proactively exploit 
the opportunities provided by the geographical proximity of 
the two agencies, while safeguarding the autonomous legal 
personality and capacity assigned to each agency by the EU 
legislature. These developments concern in particular the 
joint procurement of shared services to increase critical mass 
and obtain better conditions (e.g. for maintenance, security, 
cleaning, the canteen and cafeteria, catering, travel agency, 
interim staff and medical services); the joint organisation of 
training activities of common interest for the staff of both 
agencies; and the sharing of some services/bodies, such as 
the EMCDDA medical officer and the invalidity and disciplinary 
committees. Following up on the economies achieved with the 
common implementation of a business continuity facility with 
EMSA, the EMCDDA is committed to extending the agreement.
As the new digital workplace programme develops, the 
EMCDDA will seek to match technological developments 
and to achieve further economies by updating its current 
infrastructure architecture. Progress in this area will depend, 
however, on the availability of resources.
l  2.7. Assessment of audit and ex post evaluation results during the reporting year
l 2.7.1. Internal Audit Service
The IAS strategic internal audit plan 2020-2022 includes two 
prospective audit topics for the EMCDDA: human resources 
management; and strategic planning and programming. The 
audit plan also includes follow-up activities and a reserve audit 
topic on international cooperation.
The IAS started the preliminary interviews for the audit on 
human resources management in November 2020. The 
fieldwork was carried out in January 2021. The objective of 
the audit is to assess the adequacy of the design and the 
effectiveness of the internal control system put in place by 
the EMCDDA to manage its human resources. The audit will 
also assess the centre’s compliance with the relevant human 
resources rules and procedures.
l 2.7.2. European Court of Auditors
The report of the ECA on the EMCDDA’s 2019 annual accounts 
confirmed their reliability and the legality and regularity of the 
transactions underlying them. In this context no finding was 
mentioned or issued.
l  2.8a. Follow-up of recommendations and action plans for audits and evaluations
In its report on the EMCDDA 2019 annual accounts the ECA 
did not mention any findings or express any observations 
requiring follow-up action by the EMCDDA.
The audit report on information technology project 
management in the EMCDDA included two ‘very important’ 
recommendations aimed at: defining and adopting 
a requirements management process; and, defining and 
adopting a systems development methodology. Both of these 
recommendations were implemented in 2019 and formally 
closed, by the IAS, in 2020.
The audit report on the management of data collection, 
validation and quality assurance in the EMCDDA included 
one ‘very important’ recommendation aiming at improving 
the definition of the agency’s business needs and identifying 
the related IT functionalities to support the data collection, 
validation and quality assurance process. The EMCDDA 
agreed with the IAS on an action plan to address the issued 
recommendation, which was adequately and effectively 
implemented. The recommendation was formally closed, by 
the IAS, in January 2020.
l  2.8b. Follow-up of recommendations issued following investigations by OLAF
The EMCDDA’s Management Board approved the Anti-fraud 
Strategy in June 2016, reflecting OLAF’s methodology and 
guidance, including the rules on internal investigations, the 
initiatives for awareness-raising on staff ethics, the rules on 
gifts and hospitality offered by third parties, the guidelines on 
serious wrongdoing and whistleblowing.
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The strategy took into account the priorities set by the 
European Commission within the framework of the Common 
Approach on EU decentralised agencies, especially: the proper 
handling of conflicts of interests and the development of 
anti-fraud activities through prevention, detection, awareness-
raising and closer cooperation with OLAF.
Since its creation, there were no cases of fraud in the Centre 
and the degree of exposure of the EMCDDA to the risk of fraud 
can be generally considered as relatively reduced.
The EMCDDA has not been the subject of an OLAF 
investigation in previous years and, therefore, there are no 
standing recommendations.
l  2.9. Follow-up of observations from the discharge authority
l  Measures taken in light of the observations accompanying the decision on the discharge to the EMCDDA for 2018
Observation No 16 of the discharge decision
Notes with concern that, according to the Centre, several 
recommendations included in the 2015 IAS audit on IT project 
management have been only partly implemented and that, at 
the end of 2018, two recommendations were still outstanding; 
notes, however, that those two recommendations were 
expected to be implemented by mid-2019; calls on the Centre 
to report to the discharge authority on the progress achieved 
by June 2020;
Measure taken by the EMCDDA to follow up on 
Observation No 16
All recommendations emerging from the referred IAS’s audit 
have been implemented, and were formally closed in January 
2020.
Observation No 17 of the discharge decision
Notes that, according to the Court’s report, pursuant to 
Directive 2008/104/EC2 and Portuguese labour law, interim 
workers should work under the same working conditions as 
workers employed directly by the user undertaking; notes, 
however, that the relevant contracts did not explicitly require 
the temporary work agencies to respect those conditions 
and that there is no evidence that the Centre itself carried 
out any comparison between the working conditions of its 
own staff and those of interim staff, which undermines safe 
and predictable working conditions for the staff and causes 
a risk of litigation and risks for the Centre’s reputation; notes 
that, according to the Centre’s reply, the contract between the 
Centre and the temporary work agency refers to the obligation 
of the Centre to comply with all aspects of the applicable 
legislation and that, pursuant to that contract, the temporary 
work agency is the party exposed to the risks of litigation; 
highlights, however, that this type of situation still carries 
high reputational risks for the Centre; welcomes the fact that 
the Centre is reassessing its policy for the use of temporary 
workers to base that policy more on the law of the Member 
State in which the Centre is located, in line with its operating 
needs and the legal framework; calls on the Centre to analyse 
the working conditions of its interim staff and ensure that 
those conditions are in line with Union and national labour law; 
calls on the Centre to report to the discharge authority on the 
progress achieved by June 2020;
Measure taken by the EMCDDA to follow up on 
Observation No 17
The EMCDDA has reviewed its policy for the use of temporary 
workers by better defining/clarifying the profile/tasks of 
possible interim workers and by adopting a restrictive 
approach to the employment of such workers, whose use 
is substantially limited to meet specific essential needs for 
temporary support of an administrative or technical nature.
Furthermore, the EMCDDA has confirmed that its contract 
with the temporary work agency providing this kind of worker 
explicitly requires the latter to comply with all aspects of the 
applicable legislation, namely the Portuguese legislation that 
transposes Directive 2008/104/EC.
Observation No 18 of the discharge decision
Notes that the Union signed an agreement with Norway 
in 2006 that defines the formula to calculate Norway’s 
financial contribution to the Centre as well as the minimum 
contribution threshold which should be subject to an annual 
adjustment based on price trends and gross national income 
in the Union; notes with concern that, while the Union budget 
subsidy increased by 24 % between 2007 and 2018, Norway’s 
contribution remained almost the same; notes that, according 
to the Centre’s reply, there is no linear correlation between the 
increase of the Union subsidy and Norway’s contribution and 
that the Centre does not have the required legal capacity to 
claim a different formula/method for the adjustment of the 
minimum contribution by Norway; calls on the Centre with 
the parties concerned to adjust the minimum contribution by 
Norway in accordance with the agreed terms;
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Measure taken by the EMCDDA to follow up on 
Observation No 18
The EMCDDA has duly ensured the follow-up required for the 
technical adjustment of Norway’s minimum contribution to its 
budget, pursuant to the relevant provisions of the agreement 
between the EU and Norway for the latter’s participation in the 
work of the EMCDDA.
In particular, the EMCDDA has confirmed with the relevant 
Commission services that the method defined and applied for 
this adjustment is correct and has been correctly applied.
The application of this method has confirmed that the amount 
paid by Norway for its annual contribution to the EMCDDA 
since 2007 had never been less/lower than the adjusted 
minimum amount, as required by the relevant provisions.
Observation No 19 of the discharge decision
Calls on the Centre to focus on disseminating the results of its 
research to the public, and to reach out to the public via the 
social media and other media outlets;
Measure taken by the EMCDDA to follow up on 
Observation No 19
The EMCDDA’s website is the favoured vehicle for 
disseminating knowledge, with over 1.6 million visitors in 2020 
(see ‘Business driver 1: Institutional’). The EMCDDA has made 
great strides in making it easier for users to find content on 
the website by developing a number of key catalogues and 
repositories including: a document library for researches; 
a media library with graphics, videos and photos; and an 
events calendar rounding up drug-related conferences and 
events in Europe.
The agency’s online presence was also assured through social 
media activities. By the end of 2020 the agency had almost 
18 000 followers on Twitter, more than 12 000 followers on 
Facebook, some 1 300 followers on Instagram and nearly 
6 000 followers on LinkedIn. Videos published by the EMCDDA 
on YouTube received around 260 000 views during the year 
(and an overall increase in lifetime views of some 30 %, 
as compared to 2019). Furthermore, 37 digital campaigns 
were launched, resulting in over 68 000 individual emails to 
subscribers.
l 2.10. Environment management
The EMCDDA has actively monitored its environmental 
performance and CO
2
 footprint since 2014. Continuous 
improvement cycles have reduced its CO
2
 footprint over the 
years in comparison to the baseline established in 2014.
Annex VII to this report provides for further details on this 
matter.
l 2.11. Assessment by management
Based on the information provided in the previous subsections, 
the conclusion of the management assessment is that the 
EMCDDA’s internal procedures for budget execution and 
internal control, including the definition and implementation 
of a partially decentralised management model, in accordance 
with the EMCDDA financial regulation, which transposes in 
its entirety the text of Commission Delegated Regulation 
(EU) No 2019/715 on the framework financial regulation for 
EU agencies (see Section 2.4. above), are fully effective and 
function well.




As a follow-up to the external evaluation of the EMCDDA 
carried out during 2018, the European Commission made, on 
the basis of the report presented by an independent consultant 
(ICF International), a series of recommendations for follow-up. 
At its meeting of 12 and 13 December 2019, the Management 
Board adopted an EMCDDA action plan to follow up on these 
recommendations. The actions envisaged took into account 
the current EMCDDA mandate, as the full improvement of 
some areas may entail carrying out activities not necessarily 
covered by the existing regulation. Within this framework, 
the EMCDDA carried out a series of activities to address the 
recommendations made. Below there is a non-exhaustive 
description of the main areas covered, presented in a succinct 
manner.
In order to foster engagement with the scientific community, 
during 2020 the EMCDDA continued to contribute to 
and participate in ‘online virtual’ scientific meetings and 
conferences. It also hosted a number of technical meetings 
and webinars in which the scientific community participated. 
The EMCDDA summer school was conducted virtually, 
and a winter technical training course is also planned. The 
agency also continued to produce scientific articles that were 
accepted by high-ranking scientific journals.
The EMCDDA strived for forward-looking products by 
identifying future trends and risks to better support EU 
preparedness and response in the ever-changing drugs 
landscape, as well as communicating more directly with 
national stakeholders. Indeed, the EMCDDA futures exercise 
was completed successfully in 2020. A series of expert 
workshops were held during the year, and in 2021 the 
EMCDDA will launch a toolbox of methods to support its 
stakeholders in conducting foresight and horizon-scanning 
exercises. In addition, three data development projects were 
established in 2020 to increase preparedness in the areas of 
drug trends, policy and practice.
The EWS continues to follow up rapidly on new drugs identified 
in Europe, and remains an important tool in identifying the 
appearances of new substances and supporting the EU’s 
legislative actions on control measures.
The agency continued, as far as possible, to help develop more 
timely and sensitive data collection tools, and data from these 
instruments was given greater prominence in its publications, 
as is evident in the European Drug Report 2020.
A number of trendspotting exercises have been launched in 
response to COVID-19, and the agency has received a great 
deal of praise for its performance in rapidly monitoring 
developments in drug use.
A number of rapid analyses were produced in the context of 
EMCDDA capacity-building projects. These have provided early 
warnings on important new developments.
The EMCDDA continued to monitor and follow up on 
important policy developments. Work in the cannabis area 
is a particularly good example of this, and includes the 
preparation of a publication on low-tetrahydrocannabinol 
(THC) products. Input has also been provided into new 
developments in this area at the request of the Council and of 
Commission services.
To strengthen its communication with key stakeholders, the 
agency initiated a series of webinars on subjects such as 
the impact of COVID-19, and these will be continued in the 
future on topics of interest to the EMCDDA’s primary customer 
groups.
Furthermore, the EMCDDA pursued the implementation of two 
technical cooperation/assistance projects with priority third 
countries – IPA 7 (2019–2021) and EU4MD (2019–2022) – 
under which a series of activities were carried out to identify 
and report on future trends in the drug market.
To increase the comparability of information and data, further 
the use of visual aids and improve the quality of translation, 
a new graphic-rich product, entitled European Drug Report 
2020 – Key issues, was developed to accompany the main 
trends and developments report, and was published in 24 
languages.
A number of technical and scientific reports were translated to 
increase their dissemination potential.
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Work on the agency’s digital strategy highlighted ways in which 
it can optimise its channels and engage more with customers 
through the EMCDDA’s digital newsletters and social media 
work. It proposed piloting podcasts and producing more 
audiovisual material.
The development of online/virtual events was prioritised, and 
an online edition of the European Drug Report 2020 launch 
was organised in which more than 400 people were able to 
participate. Specialised training for staff in producing engaging 
virtual events was organised to equip them with the skills that 
they need.
Further work was undertaken to assess how to provide more 
multilingual content, including an analysis of who currently 
accesses the translated products.
The media is an important conduit for informing the general 
public. Various landscaping initiatives have been undertaken 
to improve the EMCDDA’s reach via this channel, with an 
expansion to online sources such as blogs.
The NFPs contributed to the rapid dissemination at the 
national level of the ‘EMCDDA update on the implications of 
COVID-19 for people who use drugs (PWUD) and drug service 
providers’ by translating it into their national languages.
Improving the understanding and reporting on polydrug use 
has been given greater focus throughout the EMCDDA’s 
technical work programme, insofar as this has been possible in 
the context of the current resources and mandate. In particular, 
greater attention has been paid to this issue in the agency’s 
work on monitoring fatal and non-fatal drug overdoses. The 
development of new methods, for example the analysis of 
syringe residues, has also generated new opportunities for 
reporting on this topic. The EMCDDA is also exploring how 
to better measure and report on polydrug use. This will be 
helpful in informing our reporting with respect to new EU drugs 
strategy for 2021–2025.
In order to further develop work at the international level 
in line with the agency’s mission, the EMCDDA has again 
collaborated with the ESPAD group on reporting on drug, 
alcohol and tobacco use among school students. The 2020 
reporting exercise therefore provides valuable information on 
issues related to this recommendation. EMCDDA continues to 
have access to ESPAD’s harmonised international database, 
which includes detailed information on patterns of polydrug 
use and associated factors. A number of new analyses have 
been produced that utilise these data.
The EMCDDA’s triennial single programming document 
continues to include activities developed in cooperation 
with partners, and underlines the added value this joint work 
provides to the EU.
In context of the EWS on NPS, information exchange has been 
ongoing with the Reitox network of EWS correspondents, 
the ECDC, the ECHA, the EFSA, the EMA and Europol. Some 
international partners have also been involved with these 
activities on an informal basis.
The latest edition of the EMCDDA–Europol Drug Markets 
Report addressed the international dimension of the drug 
problem, as does the preparatory work for the forthcoming 
edition of this publication. Similarly, Health and Social 
Responses to Drug Problems – A European guide, a new 
version of which is also in preparation, includes consideration 
of the international evidence base.
The agency also continues to cooperate at an international 
level alongside the International Network on Health and 
Hepatitis in Substance Users, the European Association for the 
Study of the Liver, the Correlation European Harm Reduction 
Network and other projects and networks.
Further improvements were made to reach national 
stakeholders, policymakers, practitioners and the general 
public. The Best Practice Portal continued to be revised and 
updated with the latest evidence and tools, and a new focus 
on implementation experiences. It is anticipated that the 
translation of materials into national languages will continue.
A new edition of the Health and Social Responses to Drug 
Problems – A European guide (for publication in 2021) will 
support national stakeholders with state-of-the-art information 
in the health and social responses area. Indeed, the guide is 
being reconceived to be more accessible for its users, and will 
be better integrated into the website, with access to further 
resources via a toolbox approach.
There has been enhanced engagement and dialogue on social 
media with members of the general public, who were given 
the opportunity to send questions to the EMCDDA about the 
impact of the COVID-19 pandemic on drug users and drug 
services.
In the area of drug supply, the focus remained on improving the 
quality and coverage of data collected in the Member States.
In the security area, significant progress has been made in 
addressing methodological needs and knowledge gaps in the 
use of darknet markets for the supply of drugs and the use of 
open-source information (in cooperation with the Commission 
and Europol).
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Furthermore, the EMCDDA has put additional emphasis on the 
production of short, topic-specific briefings (e.g. on violence 
and on methamphetamine production in Europe and in third 
countries) to assist the EU institutions.
Furthermore – and in addition to the EU4MD and IPA 7 
projects that provide useful information for monitoring and 
understanding the global dimension because of the direct 
impact it has on the EU drug situation – the EMCDDA has 
kept abreast of the latest developments in other regions of the 
world by engaging in activities with priority countries and with 
international organisations.
At the corporate level, streamlined ICT tools relating to time 
management and appraisal have been developed and fully 
deployed, along with an annual training policy/plan.
Furthermore, and within the context of the constraints 
entailed by the ongoing COVID-19 pandemic, the processes 
for managing the EMCDDA’s financial operations (namely 
payments) have been further digitalised and streamlined. This 
has involved, in particular, the development of a simplified 
electronic workflow where the payment procedure is processed 
on the basis of a digitalised version of the original paper-based 
supporting documents and the number of financial actors 
and steps involved is reduced to the minimum required by the 
relevant financial regulation.
Similar electronic workflows have also been put in place for 
the administrative procedures applicable to managing the 
entitlements and obligations of EMCDDA staff.
III
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PART III
Assessment of the effectiveness 
of the internal control systems
l  3.1. Effectiveness of the internal control systems
The EMCDDA’s Management Board formally adopted 
the internal control standards (ICS) in July 2010, and the 
new Internal Control Framework (ICF) in December 2017. 
Both documents were transposed by analogy and are 
fully consistent with the equivalent standards, principles 
and guidelines laid down by the European Commission. 
The ICS and the ICF constitute the basis for assessing the 
effectiveness of the internal control system at the EMCDDA, 
as provided for in Article 30 of its financial regulation (Decision 
of the Management Board of the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) to adopt the new 
financial regulation of the EMCDDA).
The ICF consists of five interrelated components and 17 
principles aimed at providing reasonable assurance in relation to 
the: 1. effectiveness, efficiency and economy of the operations; 2. 
reliability of reporting; 3. safeguarding of assets and information; 
4. prevention, detection, correction and follow-up of fraud and 
irregularities; 5. adequate management of risks relating to the 
legality and regularity of the underlying transactions.
The overall assessment of the internal control system 
depends on the assessment at the level of the principles 
and components. Besides the ongoing monitoring of internal 
control, embedded in the business processes of the centre, 
the EMCDDA performs a yearly assessment of the state 
of play of the ICS/ICF, which covers all control principles 
and components: control environment; risk assessment, 
including the risk of fraud; control activities; information and 
communication; and monitoring activities.
A comprehensive document that reviews and sets out the 
progress made in implementing the EMCDDA’s ICS was drawn 
up in early 2013. This document was updated regularly after that 
point, until 2017. Following the adoption of the ICF, a document 
with a full repository of the state of play of implementation of 
the 17 ICF principles was drafted in 2018. This document is 
updated regularly on the basis of needs and opportunity.
The result of the 2020 assessment is that all components 
are present and functioning. The assessment identified 
two principles where some improvements may be needed, 
in relation to control activities and information and 
communication. This does not affect the overall effectiveness 
of the internal control system. The EMCDDA is taking the 
necessary corrective actions to improve the underlying 
shortfalls that have been identified.
The EMCDDA had to face, as did all the other EU institutions 
and bodies, the effects of an unforeseen pandemic 
(COVID-19). With the activation of the BCP, and within its 
framework, the EMCDDA further improved certain areas in 
order to carry out control activities and to ensure the efficient 
and effective circulation of information and communication at 
both the internal and the external level. This involved adapting 
the EMCDDA’s activities at both the operational and the 
support level to fulfil the EMCDDA’s mission.
The Director established an EMCDDA task force to coordinate 
the agency’s public health response to the COVID-19 
pandemic in early March 2020. This was after activating 
the agency’s contingency management plan and putting in 
place measures to ensure the safety of the EMCDDA’s staff 
and business continuity. Once the BCP was in place, the 
agency began to consider the impact of the pandemic on 
its substantive work. This is an ongoing task, because the 
situation is continuing to develop in ways that require the 
EMCDDA to review and recalibrate its response.
At the transversal level, the EMCDDA developed a flexible 
and overarching framework to help address the issue in 
a structured manner. This involved focusing on the impact of 
the pandemic and responses to it on the agency’s plans and 
work programme, along with prioritising information-provision 
and impact-monitoring activities in a way that is flexible, rapid 
and useful for our different stakeholders.
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This framework has a number of overlapping pillars.
1. Providing an immediate response to support stakeholders 
and to facilitate communication on drug-related issues by 
establishing a dedicated set of online resources.
2. Starting a process to review the impact of the situation on 
our current substantive activities and planning to ensure 
core activities are protected and risks and problems are 
mitigated.
3. Considering the implications of the current situation on the 
need to monitor and respond on:
(a) impact on service provision and help-seeking behaviour;
(b) patterns of drug use and associated problems;
(c) drug markets.
4. Ensuring coordination and synergy between substantive 
activities in this area and implementing a number of rapid 
outputs and services.
An overview of the activities focusing on the EMCDDA’s role as 
a conduit for rapid, objective and reliable information on this 
swiftly evolving situation, along with rapid assessment and 
monitoring activities, is presented in other sections of this report.
Ultimately, the internal controls have proved effective and 
resilient throughout the COVID-19 pandemic. After the 
activation of the BCP, within that framework, the agency:
  set teleworking as the default working mode, except for 
critical functions;
  ensured regular contact with staff and provided them with 
guidance via email and virtual meetings;
  created a dedicated intranet page for COVID-19; launched 
a staff well-being survey online;
  used remote tools to conduct recruitment;
  prepared ‘Guidelines for returning to work on the 
premises’;
  deprioritised some lower-level priorities;
  participated in the EU Agencies Network’s COVID-19 
working group to ensure the use of resources among 
agencies was maximised.
Furthermore, the risk management process was a central 
element in the system of internal control and, as in previous 
years, a comprehensive risk identification and assessment 
exercise aimed at improving risk management at the 
EMCDDA was carried out in 2020. The central risk register 
was updated regularly. This register identifies, for each area, 
the estimated risk level, impact and response; the mitigating 
measures currently in place; and the list of programmes, 
projects and actions that will contribute to reducing the 
outstanding residual risk levels. Risk assessment was carried 
out continuously at the EMCDDA throughout the year, while 
a comprehensive analysis was performed by the managers in 
the context of preparing the single programming documents.
The following developments in 2020 contributed to the overall 
effectiveness of the internal control systems.
  Implementation of measures aimed at improving project 
management in the EMCDDA, particularly in the ICT 
sector.
  Consolidation of the performance model based on 
a limited number (10) of composite KPIs, that is, KPIs 
built on and measured by sets of underlying lower-level 
performance indicators. This new performance model was 
first presented in the EMCDDA’s Programming Document 
2019–21.
  Progressive deployment of Matrix as a corporate 
management information system for operational planning, 
monitoring and reporting of activities.
  Internal EMCDDA coordination mechanisms (e.g. the 
heads of unit meetings, editorial board meetings, product 
coordinating meetings, ICT Steering Committee meetings 
and scientific coordination meetings) further contributed 
to strengthening risk management processes by 
enhancing the capacity of managers and other key staff to 
closely monitor all major issues relating to the timely and 
effective implementation of planned activities, the delivery 
of outputs and the achievement of results.
  Drafting and formalisation of the strategy for the 
organisational management and internal control systems, 
included as an annex to the Single Programming 
Document 2021–2023, in line with the applicable 
guidelines issued by the Commission;
  Start of the process to review the EMCDDA’s anti-fraud 
strategy, which is expected to be carried out during 2021. 
For further information on the EMCDDA’s anti-fraud 
strategy, please refer to Section 2.8b above.
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In terms of the prevention and management of conflicts of 
interest, the EMCDDA’s Management Board adopted a revised 
policy in December 2014 that reflects the common approach 
endorsed by the Parliament, the Council and the Commission 
in July 2012, calling for the development and application in all 
EU decentralised agencies of a coherent policy on preventing 
and managing conflicts of interest concerning the members 
of the Management Board, the members of the Scientific 
Committee and the agencies’ directors.
The policy took into account the main recommendations 
addressed to agencies in this area by the European Parliament 
(namely within the framework of the discharge process), 
the European Court of Auditors (in its Special Report 
No 15/2012 – Management of conflict of interest in selected 
EU agencies), the European Ombudsman (on the occasion 
of the Ombudsman’s visits to several agencies, as part of 
a programme launched in May 2011) and the Commission’s 
IAS, in its capacity as the internal auditor for the agencies.
The Commission worked closely with the agencies to prepare 
a model for guidelines on the prevention and management of 
conflict of interests in EU decentralised agencies. In particular, 
the network of the Heads of EU Agencies contributed to 
this preparation by gathering information about agencies’ 
experiences and best practices in this field.
The agency also has in place conflict-of-interest policies 
applicable to its statutory staff, who are bound by the Staff 
Regulations (e.g. at the moment of taking up duty, conflict of 
interest of spouses, during recruitment processes).
l  3.2. Conclusions of the assessment of internal control systems
Based on the information provided under Section 3.1 above, 
the overall result of the management assessment of the 
effectiveness of internal control system as a whole is that it is 
fully effective and functioning well.
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l  3.3. Statement of the manager in charge of risk management and internal control
l Statement of the Manager in charge of risk management and internal control
I, the undersigned,
In my capacity as Manager in charge of risk management and internal control within the EMCDDA, I declare that in accordance with 
the EMCDDA’s Internal Control Framework, I have reported my advice and recommendations on the overall state of internal control 
in the agency to the Executive Director.
I hereby certify that the information provided in the present General Report of Activities and in its annexes is, to the best of my 
knowledge, accurate, reliable and complete.
Done in Lisbon on 30 April 2020
Fabian Pereyra 
Head of the Executive Office
IV




l  4.1. Review of the elements supporting assurance
The declaration of assurance of the authorising officer is based 
on the following combination of external and internal oversight 
and control procedures over the EMCDDA’s organisation and 
activities.
  The assessment of the effectiveness of the internal control 
system.
  The risk management exercise.
  The statement of the manager in charge of risk 
management and internal control.
  The accounting officer’s certification of the 2020 
provisional accounts.
  Assurance provided by the ECA’s audit: no preliminary 
observations as regards to the 2020 audit and no open 
observations from prior years (5).
  Assurance provided by the IAS audit: no ‘critical’ or ‘very 
important’ recommendations outstanding from the IAS 
audits, at year-end.
  Progress in implementing the recommendations of the 
external evaluation.
  Ex ante controls.
  The register of exceptions.
(5) There is one observation in relation to which, ‘The eCA takes account of the 
existence of a pending case before the CJeU, addressing several questions 
concerning the application of Directive 2008/104/eC of the european Par-
liament and of the Council of 19 November 2008 on temporary agency work 
to eU agencies. Since the reply to those questions by the CJeU may have 
an impact on the eCA’s position as regards the use of interim workers by the 
eMCDDA, the eCA refrains from making follow-up on observations from pre-
vious years concerning this matter, until the CJeU rendered its ruling in that 
case.’
  The EMCDDA’s anti-fraud strategy and the policy for the 
prevention and management of conflicts of interest.
The aforementioned building blocks do not identify any 
significant weaknesses that could impact the declaration of 
assurance of the authorising officer.
l 4.2. Reservations
A reservation in the declaration of assurance is prompted by 
the occurrence of significant internal weaknesses or external 
events that lead to the materialisation of critical risks.
At the EMCDDA, critical risks are events that have the potential 
to:
  jeopardise the realisation of major policy objectives;
  cause serious damage to the centre’s stakeholders;
  require critical intervention from the Parliament, the 
Council or the Commission regarding the centre’s 
performance;
  result in critical observations/recommendations from the 
European Court of Auditors, the IAS and the European 
Anti-Fraud Office;
  result in the breaching of laws and the pervasive 
infringement of regulations;
  result in material financial loss;
  put the safety of the centre’s staff at risk;
  seriously damage the centre’s reputation and image;
  cause any other event that, due to its likelihood and 
impact, is assessed, by the management, as critical to the 
achievement of the organisational objectives.
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None of these risks materialised at the EMCDDA in 2020.
The assessment of materiality involves a qualitative and 
a quantitative judgement, and the occurrence of any critical 
risk is material per se. Qualitative elements taken into account 
include the nature of the event, its recurrence, its duration and 
its effect on the activities and programmes of the EMCDDA. 
Quantitative elements are assessed based on budgetary 
considerations. The EMCDDA is continuously looking to adjust 
and refine the concrete criteria to assess materiality.
In 2020 the EMCDDA identified medium to high risks 
related to: the COVID-19 pandemic; the Centre’s budgetary 
constraints; a lack of resources and funding for the NFPs; 
supplementary requests from EU institutions and Member 
States; suboptimal IT project and assets management; and 
a shortfall in ICT staff. To tackle each of these risks, the 
EMCDDA has taken all necessary mitigating actions. A clear 
demonstration of the efficiency and effectiveness of the 
measures taken is evidenced by the performance achieved by 
the EMCDDA in 2020, as stated in Section 2.3 ‘Budgetary and 
financial management’ above.
V
General Report of Activities 2020 Part V I Declaration of assurance
65 / 78
   l i   
PART V
Declaration of assurance
l Declaration of assurance by the authorising officer
I, the undersigned, Director of the EMCDDA,
In my capacity as authorising officer,
Declare that the information contained in this report gives a true and fair view.
State that I have reasonable assurance that the resources assigned to the activities described in this report have been used for 
their intended purpose and in accordance with the principles of sound financial management, and that the control procedures put 
in place give the necessary guarantees concerning the legality and regularity of the underlying transactions.
This reasonable assurance is based on my own judgement and on the information at my disposal, such as the results of the self-
assessment, ex post controls, the work of the Internal Audit Service and the lessons learnt from the reports of the Court of Auditors 
for years prior to the year of this declaration.
Confirm that I am not aware of anything not reported here which could harm the interests of the agency.
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Annexes
l  Annex I Core business statistics
l  Annex Ia Implementation of the 2020 work programme by objectives and expected outputs/results
This annex is available online.
l  Annex Ib Key performance indicators
This annex is available online.
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l  Annex II Statistics on financial management
l Calculation of budget outturn
TABLe 6. Budget outturn and cancellation of appropriations
Budget outturn 2018 2019 2020
Reserve from the previous years’ surplus (+) 189 764 22 251 20 639
Revenue actually received (+) 16 169 483 18 195 649 18 058 665
Payments made (–) – 16 009 622 – 16 525 529 – 16 972 131
Carryover of appropriations (–) – 455 152 – 1 777 308 – 2 494 470
Cancellation of appropriations carried over (+) 27 093 12 561 23 407
Adjustment for carryover of assigned revenue
appropriations from previous year (+) 292 360 115 167 1 494 794
Exchange rate differences (+/–) – 1 911 99 – 2 229
Adjustment for negative balance from previous year (–) – 189 764 – 22 251 – 20 639
TOTAL 22 251 20 639 108 036
l Descriptive information and justification
— Budget outturn. The amount of budget outturn was limited as a result of the very high rate of budget execution in 2020.
— Cancellation of commitment appropriations. In 2020 commitment appropriations amounted to total 17 021 083 EUR 
(commitment appropriations from C1 fund source). The EMCDDA was able to commit 17 020 470 EUR of these appropriations. 
The non-committed amount from the whole 2020 financial envelope is EUR 613, thus 99,996 % implementation of commitment 
appropriations in 2020 and rate of cancellation of C1 commitments: 0,004 %.
— Cancellation of payment appropriations for the year and payment appropriations carried over.
The payment appropriations for 2020 amounted to a total of EUR 17 297 999, of which:
  EUR 17 021 083 from C1 fund sources;
  EUR 276 916 from C8 fund sources (i.e. appropriations carried forward from 2019 under budget titles 1 and 2).
In line with the excellent performance of the previous years, the EMCDDA was able to use 99.35 % of these appropriations, i.e. 
EUR 17 184 883, as follows:
  EUR 16 124 654 from 2020 C1 fund sources for payments executed in 2020;
  EUR 253 509 from C8 fund sources (committed in 2019) for payments executed in 2020;
  EUR 806 720 carried forward to 2021 for payments to be executed in 2021.
The cancelled payment appropriations for 2020 were EUR 113 115, or 0.65 %, expressed as a share of total payment credits for 
2020.
Without considering the assigned appropriations, no payment appropriations were carried over and cancelled.
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l  Annex III Organisational chart
FIgURe 20. Organisational chart
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l  Annex IV Establishment plan and additional information on human resources management
TABLe 7. Information on recruitment grade / function group for each type of post
Key functions
Type of contract 
(official (O), temporary 
agent (TA) or contract 
agent (CA))
Function group (FG), recruitment 
grade *
Indication whether the function is 
dedicated to administrative support 
or operations
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Secretary to the Director O, TA, CA
AST 1, Fg II
(internal, inter-agency, external)
Operational
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TABLe 8. Job screening/benchmarking against previous year’s results
(as per methodology for agencies job screening (2014))
Job type (sub)category Year n – 1 (%) 2019 Year n (%) 2020
Administrative support and coordination 19.11 % 18.25 %
Administrative support 18.45 % 17.61 %
Coordination 0.67 % 0.64 %
Operational 71.07 % 72.24 %
Top-level operational coordination 4.33 % 4.19 %
Programme management and Implementation 54.59 % 57.10 %
evaluation and impact assessment 0 % 0 %





  Decision DEC/MB/20/01 of the Management Board of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) on the EMCDDA general implementing provisions on the duties of Commission drivers.
  Decision DEC/MB/20/03 of the Management Board of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) on the EMCDDA general implementing provisions on leave.
  Decision DEC/MB/20/10 of the Management Board of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) on the general implementing provisions for Articles 11 and 12 of Annex VIII to the Staff Regulations on the transfer of 
pension rights.
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l  Annex V Human and financial resources by activity




Main actors for 
implementation/ 
cost objects




















HeA, SAS, SDI, 
RTX&eP, COM, ICT, 
DIR/eXO
2.65 23.2 9.5 0 35.35 5 532 341 5 532 908 3 968 662
Main area: 
Security
SAS, SDI, HeA, 
RTX&eP, COM, ICT, 
DIR/eXO




DIR/eXO, SDI, COM, 
RTX&eP, ADM, ICT, 
HeA, SAS
5.75 29.85 15.1 0 50.7 8 203 703 8 204 544 10 773 883
Total 9 63 27 1 100 17 019 339 17 021 083 17 021 046
General Report of Activities 2020 Annexes
73 / 78
l  Annex VI Contribution, grant and service-level agreements. Financial framework partnership agreements
TABLe 10. Contribution, grant and service-level agreements in 2020






amount Duration Counterpart 2019 2020
Grant agreements
CA PA CA PA
Grant RTX – 











Belgium 1.6.20 79 590 31.12.20 SCIeNSANO
Amount 
CA/PA






Bulgaria 1.6.20 79 590 31.12.20
NATIONAL CeNTeR OF 






















Czechia 79 590 31.12.20 CeSKA RePUBLIKA
Amount 
CA/PA





























Finland 20.6.20 79 590 31.12.20
FINNISH INSTITUTe 









General Report of Activities 2020 Annexes
74 / 78






amount Duration Counterpart 2019 2020
Grant agreements
CA PA CA PA
Grant RTX – 
France 1.6.20 79 590 31.12.20
OBSeRVATOIRe 
FRANCAIS DeS 










Germany 1.6.20 79 590 31.12.20


























Hungary 20.7.20 79 590 31.12.20 MAgYARORSZAg
Amount 
CA/PA

















Italy 1.6.20 79 590 31.12.20 RePUBBLICA ITALIANA
Amount 
CA/PA






Latvia 1.6.20 72 760 31.12.20
SPKC DISeASe 
PReVeNTION AND 










Lithuania 1.6.20 79 590 31.12.20
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amount Duration Counterpart 2019 2020
Grant agreements
CA PA CA PA
Grant RTX – 


























Poland 20.7.20 79 590 31.12.20
KRAJOWegO 


























Romania 1.6.20 79 590 31.12.20
































Spain 7.9.20 79 590 31.12.20 ReINO De eSPANA
Amount 
CA/PA






Sweden 1.6.20 79 590 31.12.20
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amount Duration Counterpart 2019 2020
Grant agreements
CA PA CA PA
Grant RTX – 
Croatia 1.6.20 46 100 31.12.20
CROATIAN NATIONAL 









Total RTX grant agreements
Amount 

















1 197 414 1 197 414 1 007 367 1 007 367
Number 
of CA
5 5 5 5
Number 
of SNes





38 844 eUROPeAN COMMISSION
Amount CA/PA 31 040 31 040 38 844 38 844
Number of CA
Number of SNes
SLA-DG BUDG (ABAC) 48 000 eUROPeAN COMMISSION
Amount CA/PA 49 000 49 000 48 000 48 000
Number of CA
Number of SNes
SLA-Training 3 500 eUROPeAN COMMISSION
Amount CA/PA 8 374 5 074 3 500 3 676
Number of CA
Number of SNes






Amount CA/PA 90 000 90 000 18 000 18 000
Number of CA
Number of SNes
SLA ID CARDS 1 652 eUROPeAN COMMISSION
Amount CA/PA 474 154 1 652 635
Number of CA
Number of SNes
SLA EMCDDA - EUROPOL 
SIENA (MOU) 2 466
eUROPeAN UNION 








2020 24 480 eUROPeAN COMMISSION
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l  Annex VII Environment management
l  Context of the agency and its environmental management strategy
The EMCDDA is part of the Group of Justice and Home 
Affairs Agencies under DG Migration and Home Affairs. As 
such, the EMCDDA has no direct mandate related to the 
environment. The EMCDDA recognises that the agency, as 
a public institution, needs to actively monitor its environmental 
performance and implement appropriate measures to reduce 
its impact on the environment. Following the adoption 
of the environmental policy of the EMCDDA, a yearly 
policy compliance report and a report on the progress on 
environmental measures will be conducted as part of the 
annual work plan review process. Furthermore, a Working 
Group on Environment was appointed by the Director.
Environment policy of the EMCDDA
The EMCDDA, in response to the growing need to preserve 
and improve the environment, and to the calls for its protection 
made by an increasingly environmentally aware and concerned 
society, is committed to reducing its negative environmental 
impact and to continually improving its environmental 
performance as an important part of its operating methods.
For this purpose, the key principles and objectives of the 
EMCDDA’s environmental policy can be summarised as 
follows.
  Comply with or exceed the requirements of current 
environmental legislation, in particular the legislation 
applicable to the EMCDDA.
  Minimise waste by evaluating operations and ensuring 
they are as efficient as possible, and actively promote 
reuse or recycling both internally and among the centre’s 
visitors and suppliers.
  Encourage efficient use of energy, utilities and natural 
resources, especially where these are non-renewable.
  Operate and maintain the vehicle(s) of the agency and 
adopt a travel policy with due regard to environmental 
issues; encourage the use of alternative means of 
transport and car sharing as far as reasonably practical.
  Purchase and procure products that do the least damage 
to the environment, namely those with eco labels or 
suppliers with environmental certificates, where possible, 
in order to minimise the environmental impact of 
production, distribution and consumption.
  Promote environmentally conscious behaviour by the staff 
of the EMCDDA and contribute to raising the awareness of 
others by adding environmental statements to work emails 
and publications.
  Establish procedures for the periodic review of 
environmental compliance, measures taken and goals 
achieved.
  Be an environmentally responsible neighbour in the 
community where the agency operates, and seek to 
identify and correct incidents or conditions that endanger 
health, safety or the environment.
  Participate in efforts to improve environmental protection 
and understanding.
  Share appropriate pollution prevention technology, 
knowledge and methods with other EU agencies.
  Consider obtaining an environmental certification for the 
EMCDDA in the long run, with due regard to the available 
resources.
l  Overview of the agency’s environmental management system
The EMCDDA’s environmental management system is loosely 
based on the EU eco-management and audit scheme.
The environmental policy frames the intention of the agency 
and creates the legal framework defining the scope of the 
environmental management system. The Director appointed 
a Working Group on Environment with a mandate to 
review, communicate and propose measures related to the 
environmental performance of the agency. The main service 
providers – the Infrastructure and Logistics sector and the ICT 
unit – plan, implement and improve the measures approved 
by the Director. There are two reporting lines within the 
envisaged environmental management system that includes 
all mapped stakeholders. The environmental performance of 
the EMCDDA is reported within the annual work plan review 
process in the form of KPIs, and through the annual publication 
of the agency’s environmental report. The findings and targets 
of the environmental report are reviewed by the Working 
Group on Environment, which then issues recommendations. 
Environmental matters are promoted and published through 
the Working Group on Environment. The use of green public 
procurement is required.
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l Environmental aspects, indicators and targets
The annual environmental report of the EMCDDA is produced 
by the Infrastructure and Logistics sector. It covers the 
following indicators, which are usually key points for public 
administrations working mostly in an office environment and 




  energy consumption,
  water consumption,
  paper consumption,
  waste production and sorting,
  canteen,
  official vehicles,





The EMCDDA has been actively monitoring its environmental 
performance and CO
2
 footprint since 2014 (see Figure 21). 
Continuous improvement cycles have reduced its CO
2
 footprint 
over the years in comparison to the established 2014 baseline. 
The following results were published in 2021 related to data 
from 2020.The exceptional good result for 2020 is achieved 
partially due to the COVID-19 related reduction in Missions 
and transport as well as the switch to CO
2
 neutral electricity 
generated from renewable energy sources.
FIgURe 21. CO
2
 footprint evolution between 2014 and 
2020 (Tonnes of CO
2
 per person)
l  Actions to improve and communicate environmental performance
The Working Group on Environment has its own intranet 
page with information on its mandate and measures to be 
implemented. It posts the yearly environmental report on this 
intranet page. Frequent awareness-raising communications 
promote environmentally friendly behaviour to staff.
Due to the application of green public procurement measures, 
contract renewals related to utilities and consumables may 
take into account more environmentally friendly solutions. For 
example, the electricity provided now delivers electricity from 
100 % renewable energy sources, compared to the 60–40 mix 
of the previous provider.  
The Working Group on Environment recommended that 
electricity consumption be improved and that solar power 
cells be installed on the roof of the building. Furthermore, 
the installation of electrical car-charging stations was 
recommended to promote the purchase of electrical cars. Both 
projects were approved by the Director in 2019. The EMCDDA 
responded by following the recommendation and implemented 
the projects in 2020. 
The environmental policy states that the EMCDDA is striving 
to obtain environmental certification in the long run, with due 
regard to the available resources. So far, the lack of a direct 
mandate and the size of the EMCDDA have prevented any 
such implementation due to unavailable financial and staff 
resources. The same lack of resources prevents the offsetting 
of the agency’s CO
2
 footprint beyond the offsetting achieved by 
the solar panel based electricity production on the roof of the 
building.
l  Annex VIII EMCDDA provisional accounts – Financial year 2020
This annex is available online (6).
(6) As available at the moment of submission of this document (i.e. 12 May 
2021) and to be replaced by the final accounts once adopted in accordance 
with the relevant financial rules
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About this report
The General Report of Activities is an annual 
publication providing a detailed progress report of 
the EMCDDA’s activities over a 12-month period. It 
catalogues the Centre’s achievements in each area 
of its annual work programme. The report is a useful 
information source for all those seeking comprehensive 
information on the Centre and its work.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction is the hub of drug-related information in 
Europe. Its mission is to provide the European Union 
and its Member States with ‘factual, objective, reliable 
and comparable information’ on drugs and drug 
addiction and their consequences. Established in 1993, 
it opened its doors in Lisbon in 1995, and is one of the 
European Union’s decentralised agencies. The Centre 
offers policymakers the evidence base they need for 
drawing up drug laws and strategies. It also helps 
professionals and researchers pinpoint best practice 
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